{"gene":"MED1","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1998,"finding":"TRAP220 (MED1) directly interacts with thyroid hormone receptor alpha (TRα) in a ligand-dependent manner, mediated through the C terminus of TRα and the LXXLL domains of TRAP220; it also shows ligand-dependent interactions with VDR, RARα, RXRα, PPARα, PPARγ, and ER. A fragment containing the LXXLL motifs acts as a dominant negative inhibitor of nuclear receptor-mediated transcription both in transfected cells and cell-free transcription systems.","method":"GST pulldown, co-immunoprecipitation, cell-free transcription assay, transfection/dominant-negative analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal in vitro and in vivo methods, replicated across many subsequent studies","pmids":["9653119"],"is_preprint":false},{"year":2000,"finding":"Each of the two LXXLL-containing receptor binding domains (RBD-1 and RBD-2) of TRAP220 is differentially preferred by specific nuclear receptors: RXR prefers RBD-1, while TR, VDR, and PPARs strongly prefer RBD-2 in an AF2-dependent manner. Preference for RBD-2 is determined by basic-polar residues N-terminal to the LXXLL core. Both RBD-1 and RBD-2 are required for optimal association of TRAP220 with RXR-TR or RXR-VDR heterodimers on DNA.","method":"Site-directed mutagenesis, GST pulldown with recombinant proteins, in vitro transcription assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis, multiple receptors tested, consistent with structural data","pmids":["10891484"],"is_preprint":false},{"year":2000,"finding":"TRAP220 (MED1) is an essential component required for mouse development; Trap220-null mice die during early gestation with heart failure and impaired neuronal development. Primary embryonic fibroblasts from null mutants show impaired cell cycle regulation and a prominent decrease of thyroid hormone receptor function that is restored by ectopic TRAP220, but no defect in activation by Gal4-RARα/RXRα, p53, or VP16, indicating activator-selective function.","method":"Gene knockout (null mice), primary embryonic fibroblast rescue experiments, cell-free transcription assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic knockout with defined phenotype, rescue experiment, replicated by multiple labs","pmids":["10882104"],"is_preprint":false},{"year":2002,"finding":"TRAP220 (MED1) is required for PPARγ2-stimulated adipogenesis but not MyoD-stimulated myogenesis. Trap220−/− fibroblasts fail to express adipogenesis markers or PPARγ2 target genes; this is restored by exogenous TRAP220. The TRAP/Mediator complex functions directly as a transcriptional coactivator for PPARγ2 in a purified in vitro system and interacts with PPARγ2 in a ligand- and TRAP220-dependent manner.","method":"Knockout fibroblast differentiation assay, rescue by ectopic expression, purified in vitro transcription system, co-immunoprecipitation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro reconstitution plus genetic rescue, published in high-impact journal, widely replicated","pmids":["12037571"],"is_preprint":false},{"year":2002,"finding":"The TRAP/Mediator complex interacts with ERα and ERβ through TRAP220 in a ligand (17β-estradiol)-dependent manner; this interaction requires TRAP220 as shown using TRAP220−/− fibroblast extracts. An ERα–TRAP/Mediator complex was isolated from cultured cells expressing epitope-tagged ERα. The complete TRAP/Mediator complex directly enhances ER function in a highly purified cell-free transcription system.","method":"Affinity pulldown from nuclear extracts, co-immunoprecipitation from cells, TRAP220−/− fibroblast extracts, purified in vitro transcription system","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods including in vitro reconstitution and genetic null validation","pmids":["11867769"],"is_preprint":false},{"year":2001,"finding":"TRAP220 displays ERβ preference over ERα for recruitment, attributable to the binding specificity of the TRAP220 LXXLL motifs; the ER subtype-specific F-domain influences TRAP220 interaction.","method":"GST pulldown interaction assays, mutational analysis of LXXLL motifs","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal binding assays with mutants, single lab, consistent with broader LXXLL mechanism","pmids":["11303023"],"is_preprint":false},{"year":2003,"finding":"An extended 13-amino-acid LXXLL motif sequence (not just the 5-residue core) determines the nuclear receptor binding specificity of TRAP220. Swapping extended LXM sequences between TRAP220 and SRC1 alters NR binding preferences.","method":"GST pulldown interaction assays, mutagenesis of LXXLL flanking regions","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis with functional readout, single lab","pmids":["12556447"],"is_preprint":false},{"year":2004,"finding":"The N terminus of TRAP220 (MED1) is necessary and sufficient for stable association with the TRAP/Mediator complex, while both LXXLL (NR box) motifs are required for nuclear receptor (TR)-dependent transcription. Trap220−/− cells possess a relatively intact TRAP/Mediator complex that is specifically compromised in TR-dependent but not VP16-dependent transcription in vitro.","method":"Biochemical fractionation, transfection of TRAP220 deletion/point mutants in null cells, in vitro transcription assay with reconstituted complexes","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (biochemical + genetic + in vitro reconstitution) in a single rigorous study","pmids":["15340084"],"is_preprint":false},{"year":2005,"finding":"MED1/TRAP220 exists predominantly (>80% of total) in a TRAP/Mediator subpopulation that is enriched in specific subunits and tightly associated with near-stoichiometric RNA polymerase II. This MED1-containing holoenzyme supports basal- and activator-dependent transcription in vitro. MED1/TRAP220-containing versus MED1/TRAP220-deficient complexes are selectively recruited to ER versus p53 target genes. RNAi knockdown of MED1 is required for ER-mediated transcription and estrogen-dependent breast cancer cell growth.","method":"Biochemical fractionation/mass spectrometry, in vitro transcription, chromatin immunoprecipitation, RNAi knockdown","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal approaches (biochemistry, ChIP, functional RNAi) in a single rigorous study","pmids":["15989967"],"is_preprint":false},{"year":2005,"finding":"ERK (MAPK) phosphorylates TRAP220/MED1 in vivo at two specific sites: threonine 1032 and threonine 1457. ERK phosphorylation increases the stability and half-life of TRAP220/MED1, correlates with increased thyroid hormone receptor-dependent transcription, occurs in a cell cycle-dependent manner (peak at G2/M), and triggers shuttling into the nucleolus.","method":"In vivo phosphorylation mapping, cell cycle synchronization, in vitro kinase assay, transcription reporter assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — site-specific phosphorylation mapped in vitro and in vivo, functional consequences characterized, replicated in follow-up studies","pmids":["16314496"],"is_preprint":false},{"year":2005,"finding":"In Med1/Trap220-null cells, thyroid hormone (T3)-induced chromatin remodeling events at the Crabp1 locus — including juxtaposition of the TRE and GC box regions, nucleosome sliding, replacement of BRM by BRG1, and histone hyperacetylation — are all abolished, indicating a key role for TRAP/Mediator in these processes. A MED1/TRAP220-containing Mediator complex constitutively occupies the GC box region, serving as a nexus for distal and proximal factors.","method":"Chromatin immunoprecipitation, null cell genetics, chromatin remodeling assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — null cell genetics plus ChIP, multiple chromatin endpoints, consistent with broader Mediator mechanism","pmids":["16137621"],"is_preprint":false},{"year":2005,"finding":"MED1 (MED14 and MED1) are used by glucocorticoid receptor (GR) in a gene-specific manner: ladinin 1 and IRF8 induction requires both MED1 and MED14, IGFBP1 induction requires MED14 but not MED1, and GILZ induction is largely independent of both.","method":"siRNA knockdown in U2OS-hGR cells, RT-PCR of endogenous GR target genes, ChIP","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi with endogenous gene readouts and ChIP, single lab","pmids":["16239257"],"is_preprint":false},{"year":2006,"finding":"Mediator subunit Med1/TRAP220 physically interacts with the erythroid master regulator GATA-1 and is required for GATA-1-mediated transactivation. Med1-deficient embryos are anemic with defects in erythroid burst-forming units and colony-forming units but not in myeloid colonies. Mediator components occupy GATA-1-occupied enhancer sites by ChIP.","method":"Co-immunoprecipitation, transactivation assay in Med1-null cells, colony formation assay from Med1-null embryos, chromatin immunoprecipitation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic null model with specific hematopoietic phenotype, physical interaction, and ChIP, replicated in conditional knockout","pmids":["17132730"],"is_preprint":false},{"year":2008,"finding":"ERK phosphorylation of MED1 promotes its association with the Mediator complex via direct binding to the MED7 subunit; ERK phosphorylation enhances the MED1–MED7 interaction. Both thyroid and steroid hormones stimulate MED1 phosphorylation in vivo, and MED1 phosphorylation is required for its nuclear hormone receptor coactivator activity. ERK phosphorylation of MED1 enhances TR-dependent transcription in vitro.","method":"Co-immunoprecipitation of MED1 with MED7, in vivo phosphorylation by hormone treatment, in vitro transcription assay, phosphorylation-deficient mutants","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct binding partner (MED7) identified, in vitro and in vivo phosphorylation, functional consequence in transcription","pmids":["18391015"],"is_preprint":false},{"year":2008,"finding":"Med1 subunit of the Mediator complex is required for IFN-γ-induced C/EBPβ-driven transcription. Med1 associates with C/EBPβ through a domain located between amino acids 125 and 155 of its N-terminus; ERK1/2-mediated phosphorylation of C/EBPβ at Thr189 is essential for its binding to Med1, and an ERK-regulated site in Med1 is required for IFN-induced transcription.","method":"Co-immunoprecipitation, Med1 knockout cells, RNAi, mutagenesis of binding and phosphorylation sites","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (KO cells, RNAi, mutagenesis, Co-IP), single lab","pmids":["18339625"],"is_preprint":false},{"year":2009,"finding":"PGC-1α is recruited to the TRα–RXRα–UCP-1 enhancer complex through interaction of an N-terminal LXXLL domain with TRα. MED1/Mediator then displaces PGC-1α from TRα through LXXLL domain competition; upon displacement, PGC-1α remains associated with the enhancer through an interaction between PGC-1α and MED1 C-terminal domains. Med1 is required for UCP-1 induction in brown adipocytes.","method":"Biochemical competition assays, co-immunoprecipitation, chromatin immunoprecipitation, Med1 RNAi in primary brown adipocytes","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — biochemical reconstitution of competition mechanism, ChIP, and genetic knockdown in a single rigorous study","pmids":["19782026"],"is_preprint":false},{"year":2010,"finding":"MED1 LxxLL motif knockin mice exhibit severe defects in pubertal mammary gland development with loss of ERα-Mediator interaction, down-regulation of ERα-regulated genes, and impaired mammary luminal epithelial cell differentiation. MED1 is differentially expressed in different types of mammary epithelial cells.","method":"Knockin mouse model (LxxLL motif mutations), mammary gland histology, gene expression analysis, ChIP","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockin genetics with specific mammary phenotype and molecular readouts","pmids":["20351249"],"is_preprint":false},{"year":2010,"finding":"Skeletal muscle-specific Med1 knockout mice show enhanced insulin sensitivity, improved glucose tolerance, resistance to high-fat diet-induced obesity, increased mitochondrial density, and a fast-to-slow fiber switch with increased expression of UCP-1 and Cidea genes, implicating MED1 as a suppressor of energy expenditure genetic programs in skeletal muscle.","method":"Tissue-specific conditional knockout, metabolic phenotyping, gene expression profiling","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean tissue-specific KO with defined metabolic phenotype, single lab","pmids":["20479251"],"is_preprint":false},{"year":2011,"finding":"CRPC-specific enhancers drive UBE2C overexpression through MED1 recruitment. PI3K/AKT-phosphorylated MED1 mediates recruitment of FoxA1, RNA polymerase II, and TATA-binding protein to the UBE2C locus, driving long-range enhancer/promoter looping and UBE2C gene expression and cell growth.","method":"ChIP, chromosome conformation capture (3C), RNAi knockdown, phospho-mutant constructs, cell growth assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — 3C looping assay, ChIP, phospho-mutant functional rescue, multiple orthogonal methods","pmids":["21556051"],"is_preprint":false},{"year":2011,"finding":"MED1 directly interacts with the E2A activation domain and is specifically required for E2A-PBX1-dependent gene activation and leukemic cell growth. RUNX1 recruits E2A-PBX1 to chromatin and this interaction can be stabilized by EBF1.","method":"Co-immunoprecipitation, CRISPR/Cas9 MED1 depletion, transcriptome and cistrome analysis, in vitro binding assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct interaction mapped, CRISPR KO with transcriptomic readout, single lab","pmids":["33542097"],"is_preprint":false},{"year":2011,"finding":"ARGLU1 directly interacts with a far C-terminal region of MED1, co-localizes with MED1 in the nucleus, cooperates with MED1 to regulate ER-mediated gene transcription, and is recruited in a ligand-dependent manner to endogenous ER target gene promoters; co-occupancy of ARGLU1 and MED1 on the same ER target gene promoter was confirmed by ChIP-reChIP.","method":"Co-immunoprecipitation, GST pulldown, ChIP and ChIP-reChIP, reporter assay, RNAi","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct interaction with domain mapping, ChIP-reChIP co-occupancy, functional RNAi, single lab","pmids":["21454576"],"is_preprint":false},{"year":2011,"finding":"MED1 is a novel cross-talk point for HER2 and ERα pathways. MED1 is phosphorylated by HER2 signaling at a site critical for its activation. Phosphorylated MED1 is recruited to ERα target gene promoters by tamoxifen in HER2-overexpressing cells; RNAi attenuation of MED1 or mutation of its phosphorylation sites restores recruitment of corepressors N-CoR and SMRT. MED1 is also required for HER2 gene expression itself.","method":"Co-immunoprecipitation, ChIP, RNAi knockdown, phospho-mutant constructs, tissue microarray","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with phospho-mutants and RNAi, consistent mechanism, single lab","pmids":["22964581"],"is_preprint":false},{"year":2011,"finding":"T cell-specific Med1 deficiency causes a specific block in iNKT cell development but conventional αβ T cell development remains largely normal. The defect is cell-intrinsic and is rescued by ectopic Vα14-Jα18 TCR transgene expression. Thymic iNKT cells in Med1-null animals display reduced IL-2Rβ and T-bet expression.","method":"T cell-specific conditional knockout, flow cytometry, TCR transgene rescue experiment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean conditional KO with cell-intrinsic rescue, single lab","pmids":["21949387"],"is_preprint":false},{"year":2011,"finding":"Med1-specific conditional knockout in erythroid lineage causes a complete block in erythroid development (absence of β-globin gene expression) but not in myeloid or lymphoid development. Dynamic recruitment of GATA-1, TFIIB, Mediator, and RNA polymerase II to the β-globin locus was demonstrated in induced erythroid cells.","method":"Med1 conditional knockout mice, ChIP time-course in induced erythroid cells, gene expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with lineage-specific phenotype plus dynamic ChIP of Mediator at the β-globin locus","pmids":["21098667"],"is_preprint":false},{"year":2011,"finding":"MED1 is required for androgen receptor (AR)-mediated transcription through a non-canonical interaction: MED1 binds to the AR N-terminal transactivation unit-1 (Tau-1) via two newly discovered non-canonical α-helical motifs between MED1 residues 505–537, not through its two LXXLL motifs. Loss of the AR N/C intramolecular interaction decreases MED1 binding. MAPK phosphorylation of MED1 enhances the AR–MED1 interaction in prostate cancer cells.","method":"Co-immunoprecipitation with deletion/point mutants, in vitro binding assay, reporter assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — domain mapping by mutagenesis and co-IP, single lab","pmids":["22102282"],"is_preprint":false},{"year":2012,"finding":"MED1 and MED24 cooperatively contribute to pubertal mammary gland development; MED1/MED24 double heterozygous knockout mice show profound ductal branching retardation during puberty while single haploinsufficient glands develop normally. The cooperation is mediated through ER-dependent regulation of E2F1 and cyclin D1 expression.","method":"Double heterozygous knockout mouse model, mammary gland histology, gene expression analysis, reporter assay in double-mutant MEFs","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — compound genetic mouse model with defined mammary phenotype, single lab","pmids":["22331469"],"is_preprint":false},{"year":2013,"finding":"AMP-activated protein kinase (AMPK) directly interacts with Med1 and phosphorylates Med1 in vitro at serine 656, serine 756, and serine 796. AMPK also phosphorylates Med1 in vivo in mouse liver and cultured cells. AMPK inhibition decreases Med1-induced hepatocyte proliferation and PPARα activator-inducible fatty acid β-oxidation in liver.","method":"In vitro kinase assay with recombinant proteins, in vivo phosphorylation by adenoviral overexpression, AMPK inhibitor compound C, liver-specific overexpression","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — direct in vitro kinase assay with site mapping, in vivo phosphorylation confirmed, functional consequence shown, single lab","pmids":["23943624"],"is_preprint":false},{"year":2014,"finding":"Clk2 (Cdc2-like kinase 2) phosphorylates PGC-1α, which disrupts the interaction between PGC-1α and Mediator subunit MED1, suppressing PGC-1α activation of PPARα target genes in fatty acid oxidation and ketogenesis.","method":"Co-immunoprecipitation of PGC-1α–MED1 complex, in vitro kinase assay, liver-specific Clk2 knockout, primary hepatocyte manipulation","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro kinase assay, Co-IP disruption, conditional KO metabolic phenotype, single lab","pmids":["24458359"],"is_preprint":false},{"year":2015,"finding":"PRDM16 directly interacts with MED1 through its zinc finger domains, is recruited to the Ucp1 enhancer through this interaction, and enhances TR-driven transcription in a biochemically defined system in a Mediator-dependent manner. Cell-based studies confirmed MED1 and TR dependency for PRDM16-induced Ucp1 expression.","method":"GST pulldown, co-immunoprecipitation, in vitro transcription with purified components, ChIP, RNAi knockdown","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro reconstitution with direct interaction mapping, ChIP, and cell-based genetic validation in a single study","pmids":["25644605"],"is_preprint":false},{"year":2016,"finding":"cAMP-dependent protein kinase A (PKA) phosphorylates MED1 during human endometrial stromal cell (HESC) decidualization. PKA-phosphorylated MED1 interacts with ESR1 (ERα), and this phosphorylation correlates with enhanced MED1 recruitment to estrogen-responsive elements in the WNT4 gene. MED1 knockdown impairs ESR1-induced WNT4 and FOXO1 expression and blocks decidualization.","method":"Immunoprecipitation, kinase assay, ChIP, RNAi knockdown in primary HESCs","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP, ChIP, and RNAi in primary cells, single lab","pmids":["26849466"],"is_preprint":false},{"year":2019,"finding":"MED1 undergoes CDK7-dependent phosphorylation at T1457 and physically engages AR at superenhancer sites. CDK7 inhibition (THZ1) blocks AR/MED1 co-recruitment genome-wide, reverses the hyperphosphorylated MED1-associated enzalutamide-resistant phenotype, and induces tumor regression of AR-amplified CRPC in a xenograft model.","method":"ChIP-seq, co-immunoprecipitation, CDK7 inhibitor THZ1, xenograft tumor model, phospho-mutant analysis","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq, direct interaction, in vivo xenograft, phospho-specific functional analysis","pmids":["31466944"],"is_preprint":false},{"year":2020,"finding":"Structural and biophysical analyses of MED1 interaction with the VDR–RXR heterodimer bound to DNA reveal that ligand-dependent interaction between VDR and the second coactivator motif (LXM2) of MED1 is crucial for complex formation. Additionally, RXR regions interact with the structured N-terminal domain of MED1, and VDR regions outside the classical coactivator binding cleft are affected by coactivator recruitment.","method":"Structural biology (combination of methods), biophysical binding assays (SEC, native MS), mutational analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structural/biophysical characterization with mutagenesis, single lab but multiple orthogonal methods","pmids":["32990725"],"is_preprint":false},{"year":2020,"finding":"USP22 interacts with MED1 but does not deubiquitinate MED1 directly. Instead, USP22 enhances MED1 transcriptional activation functions for IL-2Rβ and T-bet gene expression through deubiquitinating histone H2A (not H2B) monoubiquitination, establishing a USP22–histone H2A deubiquitination–MED1 axis in iNKT cell development.","method":"Co-immunoprecipitation, iNKT-specific conditional knockout, ubiquitination assay, gene expression analysis","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct Co-IP, ubiquitination biochemistry, and KO phenotype, single lab","pmids":["32069354"],"is_preprint":false},{"year":2021,"finding":"KDM4B physically and functionally associates with CCAR1 and MED1 in a complex. Genome-wide ChIP-seq shows the KDM4B–CCAR1–MED1 complex is localized to promoters of osteoclast-related genes upon RANKL stimulation; the complex induces euchromatinization through H3K9 demethylation, enabling NF-κB p65 recruitment via direct interaction between KDM4B and p65.","method":"Co-immunoprecipitation, ChIP-seq, H3K9 methylation assay, conditional knockout mice, small molecule inhibitor","journal":"Bone research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP complex identification, genome-wide ChIP-seq, and KO phenotype, single lab","pmids":["34031372"],"is_preprint":false},{"year":2021,"finding":"MED1 is required for postnatal adipose expansion and induction of fatty acid/triglyceride synthesis genes when pups switch from high-fat maternal milk to carbohydrate-based chow. Mechanistically, MED1 facilitates lipogenic transcription factor ChREBP- and SREBP1a-dependent recruitment of Mediator to active enhancers. MED1 is dispensable for adipose development and for PPARγ/C/EBPα induction during adipogenesis.","method":"Adipose-specific conditional knockout, ChIP for ChREBP/SREBP1a and Mediator, gene expression profiling","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with ChIP mechanistic data, single lab","pmids":["33888555"],"is_preprint":false},{"year":2022,"finding":"MED1, when phosphorylated at T1032 by CDK9, dynamically moves with RNA polymerase II throughout transcribed genes to drive Pol II recycling after the initial round of transcription. MED31 mediates the recycling of phosphorylated MED1 and Pol II, enhancing mRNA output. MED1 phosphorylation increases during prostate cancer progression and CDK9 inhibition decreases MED1 phosphorylation and Pol II recycling.","method":"In vitro and in vivo transcription recycling assays, phospho-mutant analysis, CDK9 inhibitor, prostate cancer progression analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro reconstitution of transcription recycling, mechanistic phospho-mutant analysis, and in vivo validation","pmids":["35394046"],"is_preprint":false},{"year":1997,"finding":"RB18A (MED1/TRAP220) interacts in vitro with p53 through its C-terminal domain, binds DNA, self-oligomerizes, and regulates p53 specific binding to its DNA consensus site. RB18A activated the Bax promoter and inhibited p21Waf1 or IGF-BP3 promoters driven by p53 in vivo; RB18A interacts with p53 in vivo.","method":"Co-immunoprecipitation with p53, in vitro pulldown, transfection reporter assay with p53-responsive promoters","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and reporter assays, single lab, not extensively followed up for this specific function","pmids":["9444950","11118038"],"is_preprint":false},{"year":2004,"finding":"BRCA1's BRCT domain directly interacts with TRAP220 (MED1) in vitro and in vivo; BRCT point mutations found in patients that lack transactivation function abolish this interaction. BRCA1 transactivation function depends on TRAP220 expression levels, and antisense TRAP220 significantly reduces survival of BRCA1-expressing cells after DNA damage.","method":"GST pulldown, co-immunoprecipitation, transient expression reporter assay, BRCT point mutant analysis, cell survival assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reciprocal Co-IP and GST pulldown with functional readouts, single lab","pmids":["15208681"],"is_preprint":false},{"year":2010,"finding":"MED1 in bone marrow stromal cells supports hematopoietic stem/progenitor cells through VDR- and Runx2-mediated expression of osteopontin (OPN). Med1-null MEFs show attenuated OPN expression and Mediator recruitment to the Opn promoter; addition of OPN to Med1-null MEF co-cultures restores hematopoietic progenitor growth.","method":"Med1 knockout MEF co-culture with bone marrow cells, ChIP, gene expression analysis, OPN rescue experiment","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null cells with ChIP and rescue experiment, single lab","pmids":["20713445"],"is_preprint":false},{"year":2018,"finding":"Cardiac-specific Med1 deletion reduces RNA polymerase II occupancy at the majority of transcriptional start sites (increased pausing index) without a corresponding increase in elongating species. Med1-dependent gene expression strongly correlates with H3K27 acetylation at TSS; H3K27me3 levels are broadly increased upon Med1 deletion. Med1 determines chromatin accessibility within genes and at enhancer regions.","method":"ChIP-seq for Pol II, H3K27ac, H3K27me3 in cardiac Med1 knockout versus floxed control mice","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-seq in conditional KO, single lab","pmids":["30461303"],"is_preprint":false},{"year":2021,"finding":"Med1 controls CD8+ T cell peripheral maintenance through IL-7Rα/STAT5 pathway-mediated cell survival. T cell-specific Med1 deletion reduces CD8+ T cell proportion in spleen in a cell-intrinsic manner (competitive transfer confirmed), with increased cell death, decreased IL-7Rα expression, reduced pSTAT5, and elevated Bim.","method":"T cell-specific conditional knockout, competitive bone marrow transfer, flow cytometry, gene expression analysis","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with cell-intrinsic competitive transfer, signaling pathway readouts, single lab","pmids":["33733611"],"is_preprint":false},{"year":2022,"finding":"MED1 acts synergistically with KLF4 to transactivate BMPR2, ERG, and TGFBR2 in pulmonary endothelial cells via chromatin remodeling and enhancer-promoter interactions. EC-specific MED1 knockout mice show pulmonary hypertension susceptibility; MED1 overexpression mitigates PH phenotype in rodents. MED1 levels are decreased in lung tissue from idiopathic PAH patients.","method":"RNA-seq, MED1 ChIP-seq, H3K27ac ChIP-seq, ATAC-seq, Hi-C, endothelial-specific MED1 knockout mice, adenoviral MED1 overexpression","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multi-omic approach (ChIP-seq, ATAC-seq, Hi-C), conditional KO, and overexpression in vivo model","pmids":["36252121"],"is_preprint":false},{"year":2022,"finding":"MED1 interacts with SMAD2 and MED1 downregulation protects SMAD2 from ubiquitination-dependent degradation, thereby enhancing TGFβ/SMAD2 signaling, epithelial-to-mesenchymal transition, and metastasis in cutaneous melanoma.","method":"Co-immunoprecipitation, ubiquitination assay, RNAi knockdown, in vivo xenograft metastasis model","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP, ubiquitination biochemistry, in vivo metastasis model, single lab","pmids":["35131256"],"is_preprint":false}],"current_model":"MED1 (TRAP220) is a pivotal subunit of the Mediator coactivator complex that anchors the complex to diverse nuclear receptors (TR, VDR, PPARγ, ER, GR, AR, and others) through ligand-dependent interactions mediated by two LXXLL motifs (and, for AR, via a distinct non-canonical motif), recruits RNA polymerase II to target gene promoters, undergoes regulatory phosphorylation by ERK, CDK7, CDK9, AMPK, and PKA at specific residues to modulate its stability, complex association, and transcriptional activity, and is required for transcription of diverse gene programs controlling adipogenesis, erythropoiesis, cardiac function, mammary gland development, energy metabolism, and immune cell development—with CDK9-phosphorylated MED1 additionally traveling with Pol II to drive transcription recycling."},"narrative":{"mechanistic_narrative":"MED1 (TRAP220) is the Mediator-complex subunit that couples ligand-activated nuclear receptors and other DNA-bound activators to the RNA polymerase II transcription machinery, and it is required for diverse developmental and metabolic gene programs [PMID:9653119, PMID:10882104, PMID:15989967]. It binds thyroid hormone receptor, VDR, RAR/RXR, PPARs, and ER in a ligand-dependent manner through two LXXLL (NR-box) motifs, with individual receptors preferring RBD-1 versus RBD-2 according to residues flanking the LXXLL core, while a non-canonical α-helical motif (residues 505–537) mediates a distinct interaction with the androgen receptor N-terminal transactivation domain [PMID:9653119, PMID:10891484, PMID:12556447, PMID:22102282]. The N terminus anchors MED1 stably within the Mediator/Pol II holoenzyme, whereas the LXXLL motifs are dispensable for complex integrity but required for receptor-dependent transcription, defining MED1 as an activator-selective adaptor: Med1-null cells assemble a largely intact Mediator yet are specifically defective in TR-, ER-, PPARγ-, and GATA-1-dependent transcription while remaining competent for VP16- and p53-driven activation [PMID:10882104, PMID:15340084, PMID:15989967, PMID:12037571, PMID:17132730]. Mechanistically MED1-containing Mediator constitutively occupies target loci and orchestrates chromatin remodeling, nucleosome sliding, histone acetylation, enhancer–promoter looping, and recruitment of Pol II, TBP, and pioneer factors such as FoxA1 [PMID:16137621, PMID:21556051, PMID:30461303]. MED1 activity is tuned by a phosphorylation code: ERK phosphorylation at T1032/T1457 stabilizes MED1, promotes its MED7-dependent association with Mediator, and triggers nucleolar shuttling; CDK7 phosphorylation at T1457 drives AR co-recruitment at superenhancers; CDK9 phosphorylation at T1032 enables MED1 to travel with elongating Pol II for transcription recycling via MED31; and AMPK and PKA phosphorylate MED1 to regulate hepatic and decidualization programs [PMID:16314496, PMID:18391015, PMID:31466944, PMID:35394046, PMID:23943624, PMID:26849466]. Through these activities MED1 is genetically required for early embryogenesis and cardiac/neuronal development, adipogenesis and lipogenesis, brown-fat thermogenic gene induction, erythropoiesis and β-globin expression, mammary ductal development, iNKT and CD8 T-cell development, and pulmonary endothelial homeostasis [PMID:10882104, PMID:12037571, PMID:33888555, PMID:19782026, PMID:25644605, PMID:17132730, PMID:21098667, PMID:20351249, PMID:21949387, PMID:33733611, PMID:36252121]. It additionally serves as an integration node for cofactors and signaling partners including PGC-1α, PRDM16, ARGLU1, KDM4B/CCAR1, BRCA1, p53, and SMAD2 [PMID:19782026, PMID:25644605, PMID:21454576, PMID:34031372, PMID:15208681, PMID:9444950, PMID:11118038, PMID:35131256].","teleology":[{"year":1997,"claim":"Before MED1 was placed in Mediator, an early activity established it as a p53-associated factor capable of modulating p53 target-gene selectivity, framing it as a transcriptional regulator.","evidence":"Co-IP and p53-responsive promoter reporter assays (RB18A)","pmids":["9444950","11118038"],"confidence":"Medium","gaps":["Does not place this p53 activity within the Mediator complex","Functional significance not extensively followed up"]},{"year":1998,"claim":"Defined MED1 as a direct ligand-dependent nuclear-receptor coactivator, answering how the receptor signal reaches the basal machinery.","evidence":"GST pulldown, Co-IP, cell-free transcription, and dominant-negative LXXLL fragment across TRα, VDR, RAR/RXR, PPARs, ER","pmids":["9653119"],"confidence":"High","gaps":["Did not resolve which LXXLL motif serves which receptor","Did not establish in vivo requirement"]},{"year":2000,"claim":"Resolved the molecular basis of receptor selectivity and demonstrated organismal essentiality with activator-selective function.","evidence":"LXXLL mutagenesis defining RBD-1/RBD-2 preference, and Trap220-null mice with embryonic lethality plus rescue in null MEFs","pmids":["10891484","10882104"],"confidence":"High","gaps":["Mechanism linking MED1 loss to heart failure not defined","Cell-cycle defect mechanism not explained"]},{"year":2002,"claim":"Established gene-program-specific requirements, showing MED1 is required for PPARγ-driven adipogenesis and ER function but not all activators.","evidence":"Knockout fibroblast differentiation/rescue, purified in vitro transcription, and TRAP220-null extracts for ER","pmids":["12037571","11867769"],"confidence":"High","gaps":["Did not address how a single subunit confers program selectivity","ER subtype preference not yet resolved"]},{"year":2003,"claim":"Refined the determinant of receptor specificity to an extended 13-residue LXXLL context, explaining differential receptor recruitment.","evidence":"GST pulldown with swapped extended LXM sequences between TRAP220 and SRC1","pmids":["12556447"],"confidence":"Medium","gaps":["Structural basis not directly visualized","Single lab"]},{"year":2004,"claim":"Dissected MED1 architecture, separating complex-anchoring (N terminus) from receptor-coupling (LXXLL) functions, and clarified that null cells retain Mediator.","evidence":"Biochemical fractionation, deletion/point mutants in null cells, in vitro transcription reconstitution","pmids":["15340084"],"confidence":"High","gaps":["Did not define how the N terminus integrates into the complex structurally"]},{"year":2004,"claim":"Extended MED1 partners beyond nuclear receptors to BRCA1, linking it to DNA-damage survival.","evidence":"GST pulldown, Co-IP, BRCT point-mutant analysis, cell survival assay","pmids":["15208681"],"confidence":"Medium","gaps":["Mechanism of MED1 in DNA-damage response not defined","Single lab"]},{"year":2005,"claim":"Showed MED1 marks a distinct Pol II-associated Mediator subpopulation selectively recruited to specific genes, and linked it to ER-driven breast cancer growth.","evidence":"Biochemical fractionation/MS, in vitro transcription, ChIP, RNAi","pmids":["15989967"],"confidence":"High","gaps":["Determinants partitioning MED1 into the subpopulation unknown"]},{"year":2005,"claim":"Connected MED1 to chromatin remodeling and identified ERK phosphorylation as a stability/activity switch, beginning the MED1 phospho-code.","evidence":"ChIP/chromatin remodeling at Crabp1 in null cells; in vivo phospho-mapping at T1032/T1457, cell-cycle synchronization, kinase assays","pmids":["16137621","16314496"],"confidence":"High","gaps":["Nucleolar shuttling functional role unresolved","How remodeling enzymes are recruited not defined"]},{"year":2005,"claim":"Demonstrated gene-specific Mediator subunit usage by glucocorticoid receptor, showing MED1 dependence is target-dependent.","evidence":"siRNA in U2OS-hGR, endogenous target RT-PCR, ChIP","pmids":["16239257"],"confidence":"Medium","gaps":["Basis of gene-specific MED1 dependence unknown","Single lab"]},{"year":2006,"claim":"Established MED1 as a lineage-specific coactivator for the erythroid master regulator GATA-1.","evidence":"Co-IP, transactivation in null cells, colony assays from null embryos, ChIP","pmids":["17132730"],"confidence":"High","gaps":["Did not resolve developmental stage of requirement (addressed later)"]},{"year":2008,"claim":"Mechanistically explained ERK phosphorylation by identifying MED7 as the phospho-dependent binding partner that incorporates MED1 into Mediator.","evidence":"Co-IP of MED1 with MED7, hormone-induced phosphorylation, phospho-deficient mutants, in vitro transcription","pmids":["18391015"],"confidence":"High","gaps":["Stoichiometry/structural detail of MED1-MED7 contact not resolved"]},{"year":2008,"claim":"Broadened MED1 coactivation to a non-receptor activator (C/EBPβ) in IFN-γ signaling, with phosphorylation gating the interaction.","evidence":"Co-IP, KO cells, RNAi, mutagenesis of binding/phospho sites","pmids":["18339625"],"confidence":"Medium","gaps":["Genome-wide scope of C/EBPβ-MED1 program not defined","Single lab"]},{"year":2009,"claim":"Revealed a hand-off mechanism in which MED1/Mediator displaces PGC-1α from TRα while retaining it on the enhancer, integrating cofactors at the Ucp1 enhancer.","evidence":"Biochemical competition, Co-IP, ChIP, RNAi in brown adipocytes","pmids":["19782026"],"confidence":"High","gaps":["Dynamics of the hand-off in vivo not directly observed"]},{"year":2010,"claim":"Established the in vivo requirement of the MED1 LXXLL motifs for ERα-driven mammary development and the role in bone-marrow-stromal support of hematopoiesis.","evidence":"LxxLL knockin mice with mammary histology and ChIP; Med1-null MEF co-culture with OPN rescue","pmids":["20351249","20713445"],"confidence":"Medium","gaps":["OPN axis tested in MEFs rather than primary stroma","Knockin study single lab for mammary"]},{"year":2010,"claim":"Showed MED1 acts as a suppressor of energy-expenditure programs in skeletal muscle, defining a tissue-specific repressive metabolic role.","evidence":"Muscle-specific conditional KO, metabolic phenotyping, expression profiling","pmids":["20479251"],"confidence":"Medium","gaps":["Direct transcriptional targets in muscle not mapped","Single lab"]},{"year":2011,"claim":"Pinned the erythroid requirement to a specific developmental block and showed dynamic Mediator/Pol II recruitment at the β-globin locus.","evidence":"Erythroid conditional KO, ChIP time-course, expression analysis","pmids":["21098667"],"confidence":"High","gaps":["Why erythroid but not myeloid/lymphoid lineages depend on MED1 not fully resolved"]},{"year":2011,"claim":"Defined a non-canonical, LXXLL-independent mode of MED1 binding to AR and linked AR/MED1 to enhancer looping and oncogenic UBE2C expression in castration-resistant prostate cancer.","evidence":"Co-IP domain mapping (residues 505–537); ChIP, 3C, phospho-mutants, growth assays for UBE2C","pmids":["22102282","21556051"],"confidence":"Medium","gaps":["Structural detail of the non-canonical AR motif not resolved","PI3K/AKT phospho-site identity for UBE2C not fully mapped"]},{"year":2011,"claim":"Expanded MED1 cofactor partnerships (ARGLU1, E2A) and immune roles (iNKT development), and positioned MED1 in HER2-ER crosstalk and tamoxifen response.","evidence":"Co-IP/ChIP-reChIP (ARGLU1); CRISPR/Co-IP (E2A); conditional KO + TCR transgene rescue (iNKT); ChIP/RNAi/phospho-mutants (HER2)","pmids":["21454576","33542097","21949387","22964581"],"confidence":"Medium","gaps":["Several interactions rest on single-lab Co-IP","HER2-MED1 phospho-site precise identity not fully defined"]},{"year":2012,"claim":"Demonstrated cooperative Mediator subunit dosage (MED1+MED24) in ER-dependent mammary proliferation via E2F1/cyclin D1.","evidence":"Double heterozygous KO mice, histology, expression, reporter assays","pmids":["22331469"],"confidence":"Medium","gaps":["Direct cooperativity mechanism between subunits not defined","Single lab"]},{"year":2013,"claim":"Added AMPK to the MED1 kinase set, mapping hepatic phosphosites controlling PPARα-dependent fatty acid oxidation.","evidence":"In vitro kinase assay with site mapping (S656/S756/S796), in vivo phosphorylation, AMPK inhibition, liver overexpression","pmids":["23943624"],"confidence":"Medium","gaps":["Functional consequence of individual AMPK sites not separated","Single lab"]},{"year":2014,"claim":"Showed that kinase regulation of the PGC-1α–MED1 interface (via Clk2 phosphorylation of PGC-1α) gates hepatic fatty acid oxidation and ketogenesis.","evidence":"Co-IP disruption, in vitro kinase assay, liver-specific Clk2 KO, primary hepatocytes","pmids":["24458359"],"confidence":"Medium","gaps":["MED1 residues involved in PGC-1α binding not mapped here","Single lab"]},{"year":2015,"claim":"Identified PRDM16 as a zinc-finger-mediated MED1 partner that recruits Mediator to the Ucp1 enhancer to enhance TR-driven thermogenic transcription.","evidence":"GST pulldown, Co-IP, in vitro transcription with purified components, ChIP, RNAi","pmids":["25644605"],"confidence":"High","gaps":["In vivo requirement of the PRDM16-MED1 contact not established"]},{"year":2016,"claim":"Added PKA-dependent MED1 phosphorylation as the signal coupling ESR1 to decidualization gene expression.","evidence":"IP, kinase assay, ChIP, RNAi in primary endometrial stromal cells","pmids":["26849466"],"confidence":"Medium","gaps":["PKA phosphosite on MED1 not mapped","Single lab"]},{"year":2018,"claim":"Provided genome-wide evidence that MED1 controls Pol II promoter occupancy/pausing and chromatin state in cardiac tissue, linking it to H3K27ac/H3K27me3 balance.","evidence":"ChIP-seq for Pol II/H3K27ac/H3K27me3 in cardiac conditional KO","pmids":["30461303"],"confidence":"Medium","gaps":["Causal hierarchy between Pol II loss and chromatin changes not resolved","Single lab"]},{"year":2019,"claim":"Connected CDK7 phosphorylation of MED1 T1457 to AR superenhancer engagement and enzalutamide resistance, establishing a therapeutic vulnerability.","evidence":"ChIP-seq, Co-IP, CDK7 inhibitor THZ1, xenograft, phospho-mutants","pmids":["31466944"],"confidence":"High","gaps":["Generalizability beyond AR-amplified CRPC not addressed"]},{"year":2020,"claim":"Provided structural/biophysical resolution of MED1 engagement with DNA-bound VDR-RXR, confirming LXM2 as the critical ligand-dependent contact plus RXR–N-terminal-domain interactions.","evidence":"Structural biology, SEC/native MS, mutational analysis","pmids":["32990725"],"confidence":"High","gaps":["Full Mediator-receptor architecture not resolved","Single receptor pair"]},{"year":2020,"claim":"Defined an indirect cofactor mechanism (USP22 deubiquitinates histone H2A, not MED1) enabling MED1 activation of iNKT developmental genes.","evidence":"Co-IP, iNKT conditional KO, ubiquitination assay, expression analysis","pmids":["32069354"],"confidence":"Medium","gaps":["Direct chromatin co-occupancy of USP22-MED1 not mapped genome-wide","Single lab"]},{"year":2021,"claim":"Placed MED1 in a KDM4B-CCAR1 H3K9-demethylase complex enabling NF-κB-driven osteoclast gene activation, and expanded metabolic roles to postnatal lipogenesis via ChREBP/SREBP1a and CD8 T-cell maintenance via IL-7Rα/STAT5.","evidence":"Co-IP/ChIP-seq/KO (KDM4B); adipose conditional KO + ChIP (lipogenesis); T-cell KO + competitive transfer (CD8)","pmids":["34031372","33888555","33733611"],"confidence":"Medium","gaps":["Direct vs indirect contributions of MED1 in each complex not fully separated","Single-lab studies"]},{"year":2022,"claim":"Established the CDK9-MED1 T1032-MED31 axis driving Pol II recycling/elongation, and added vascular (KLF4-MED1) and oncogenic (SMAD2 stabilization) functions.","evidence":"In vitro/in vivo recycling assays, phospho-mutants, CDK9 inhibition (recycling); multi-omic + EC KO (KLF4/PH); Co-IP/ubiquitination/xenograft (SMAD2)","pmids":["35394046","36252121","35131256"],"confidence":"High","gaps":["How MED31 selects phospho-MED1/Pol II cargo not fully resolved","SMAD2 mechanism single lab"]},{"year":null,"claim":"How the MED1 phosphorylation code (ERK/CDK7/CDK9/AMPK/PKA at distinct residues) is integrated to dictate which activator program, complex association, and elongation/recycling outcome predominates in a given cell type remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking individual phosphosites to specific gene programs","Structural basis of activator-selective Mediator partitioning unknown","Crosstalk among the five kinases not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,8,12]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,3,4,15]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,7,13,28]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[36]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8,20]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[9]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[8,10]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,7,8,35]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[10,33,39,41]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,3,16,23]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,15,17,26,34]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,14,21,42]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,22,32,40]}],"complexes":["Mediator complex (TRAP/Mediator)","Mediator-Pol II holoenzyme","KDM4B-CCAR1-MED1 complex"],"partners":["MED7","PGC-1ALPHA","PRDM16","GATA1","ARGLU1","MED31","BRCA1","SMAD2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15648","full_name":"Mediator of RNA polymerase II transcription subunit 1","aliases":["Activator-recruited cofactor 205 kDa component","ARC205","Mediator complex subunit 1","Peroxisome proliferator-activated receptor-binding protein","PBP","PPAR-binding protein","Thyroid hormone receptor-associated protein complex 220 kDa component","Trap220","Thyroid receptor-interacting protein 2","TR-interacting protein 2","TRIP-2","Vitamin D receptor-interacting protein complex component DRIP205","p53 regulatory protein RB18A"],"length_aa":1581,"mass_kda":168.5,"function":"Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors (PubMed:10406464, PubMed:11867769, PubMed:12037571, PubMed:12218053, PubMed:12556447, PubMed:14636573, PubMed:15340084, PubMed:15471764, PubMed:15989967, PubMed:16574658, PubMed:9653119). Acts as a coactivator for GATA1-mediated transcriptional activation during erythroid differentiation of K562 erythroleukemia cells (PubMed:24245781)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q15648/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MED1","classification":"Not Classified","n_dependent_lines":812,"n_total_lines":1208,"dependency_fraction":0.6721854304635762},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"MED10","stoichiometry":10.0},{"gene":"MED11","stoichiometry":10.0},{"gene":"MED14","stoichiometry":10.0},{"gene":"MED17","stoichiometry":10.0},{"gene":"MED19","stoichiometry":10.0},{"gene":"MED21","stoichiometry":10.0},{"gene":"MED27","stoichiometry":10.0},{"gene":"MED31","stoichiometry":10.0},{"gene":"MED4","stoichiometry":10.0},{"gene":"MED8","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/search/MED1","total_profiled":1310},"omim":[{"mim_id":"616936","title":"CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 9; CHD9","url":"https://www.omim.org/entry/616936"},{"mim_id":"614135","title":"EPIPHYSEAL DYSPLASIA, MULTIPLE, 6; EDM6","url":"https://www.omim.org/entry/614135"},{"mim_id":"614046","title":"ARGININE- AND GLUTAMATE-RICH PROTEIN 1; ARGLU1","url":"https://www.omim.org/entry/614046"},{"mim_id":"612116","title":"UBIQUITIN-SPECIFIC PROTEASE 22; USP22","url":"https://www.omim.org/entry/612116"},{"mim_id":"606485","title":"POLYMERASE II, RNA, SUBUNIT M; POLR2M","url":"https://www.omim.org/entry/606485"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MED1"},"hgnc":{"alias_symbol":["PBP","TRAP220","RB18A","DRIP230","CRSP200","CRSP1"],"prev_symbol":["TRIP2","PPARGBP","PPARBP"]},"alphafold":{"accession":"Q15648","domains":[{"cath_id":"3.30.457,3.30.920","chopping":"72-163","consensus_level":"medium","plddt":83.5597,"start":72,"end":163},{"cath_id":"-","chopping":"166-351_387-427","consensus_level":"medium","plddt":85.8272,"start":166,"end":427}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15648","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15648-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15648-F1-predicted_aligned_error_v6.png","plddt_mean":50.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MED1","jax_strain_url":"https://www.jax.org/strain/search?query=MED1"},"sequence":{"accession":"Q15648","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15648.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15648/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15648"}},"corpus_meta":[{"pmid":"9653119","id":"PMC_9653119","title":"The TRAP220 component of a thyroid hormone receptor- associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9653119","citation_count":381,"is_preprint":false},{"pmid":"12037571","id":"PMC_12037571","title":"Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12037571","citation_count":279,"is_preprint":false},{"pmid":"10882104","id":"PMC_10882104","title":"Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action.","date":"2000","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10882104","citation_count":250,"is_preprint":false},{"pmid":"10097147","id":"PMC_10097147","title":"MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10097147","citation_count":216,"is_preprint":false},{"pmid":"11463373","id":"PMC_11463373","title":"Restriction of mesendoderm to a single blastomere by the combined action of SKN-1 and a GSK-3beta homolog is mediated by MED-1 and -2 in C. elegans.","date":"2001","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11463373","citation_count":160,"is_preprint":false},{"pmid":"10930409","id":"PMC_10930409","title":"Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10930409","citation_count":149,"is_preprint":false},{"pmid":"11867769","id":"PMC_11867769","title":"The TRAP/Mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function in vitro.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11867769","citation_count":134,"is_preprint":false},{"pmid":"15989967","id":"PMC_15989967","title":"MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription.","date":"2005","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/15989967","citation_count":122,"is_preprint":false},{"pmid":"16239257","id":"PMC_16239257","title":"MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor.","date":"2005","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/16239257","citation_count":112,"is_preprint":false},{"pmid":"21556051","id":"PMC_21556051","title":"Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21556051","citation_count":111,"is_preprint":false},{"pmid":"14614141","id":"PMC_14614141","title":"The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14614141","citation_count":108,"is_preprint":false},{"pmid":"20065103","id":"PMC_20065103","title":"MiR-205 silences MED1 in hypoxic primary human trophoblasts.","date":"2010","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/20065103","citation_count":108,"is_preprint":false},{"pmid":"19000668","id":"PMC_19000668","title":"Defective ciliogenesis, embryonic lethality and severe impairment of the Sonic Hedgehog pathway caused by inactivation of the mouse complex A intraflagellar transport gene Ift122/Wdr10, partially overlapping with the DNA repair gene Med1/Mbd4.","date":"2008","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19000668","citation_count":102,"is_preprint":false},{"pmid":"31466944","id":"PMC_31466944","title":"CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.","date":"2019","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/31466944","citation_count":100,"is_preprint":false},{"pmid":"11303023","id":"PMC_11303023","title":"Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ERalpha and ERbeta.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11303023","citation_count":99,"is_preprint":false},{"pmid":"10891484","id":"PMC_10891484","title":"Specific structural motifs determine TRAP220 interactions with nuclear hormone receptors.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10891484","citation_count":97,"is_preprint":false},{"pmid":"22964581","id":"PMC_22964581","title":"Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22964581","citation_count":89,"is_preprint":false},{"pmid":"15340084","id":"PMC_15340084","title":"Structural and functional organization of TRAP220, the TRAP/mediator subunit that is targeted by nuclear receptors.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15340084","citation_count":88,"is_preprint":false},{"pmid":"11267993","id":"PMC_11267993","title":"Role of MED1 (MBD4) Gene in DNA repair and human cancer.","date":"2001","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11267993","citation_count":87,"is_preprint":false},{"pmid":"11056019","id":"PMC_11056019","title":"Investigation of the substrate spectrum of the human mismatch-specific DNA N-glycosylase MED1 (MBD4): fundamental role of the catalytic domain.","date":"2000","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11056019","citation_count":84,"is_preprint":false},{"pmid":"17132730","id":"PMC_17132730","title":"The mediator complex functions as a coactivator for GATA-1 in erythropoiesis via subunit Med1/TRAP220.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17132730","citation_count":82,"is_preprint":false},{"pmid":"25644605","id":"PMC_25644605","title":"PRDM16 enhances nuclear receptor-dependent transcription of the brown fat-specific Ucp1 gene through interactions with Mediator subunit MED1.","date":"2015","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/25644605","citation_count":80,"is_preprint":false},{"pmid":"17641689","id":"PMC_17641689","title":"MED25 is distinct from TRAP220/MED1 in cooperating with CBP for retinoid receptor activation.","date":"2007","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/17641689","citation_count":75,"is_preprint":false},{"pmid":"20351249","id":"PMC_20351249","title":"Key roles for MED1 LxxLL motifs in pubertal mammary gland development and luminal-cell differentiation.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20351249","citation_count":70,"is_preprint":false},{"pmid":"20479251","id":"PMC_20479251","title":"A muscle-specific knockout implicates nuclear receptor coactivator MED1 in the regulation of glucose and energy metabolism.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20479251","citation_count":67,"is_preprint":false},{"pmid":"16137621","id":"PMC_16137621","title":"Thyroid hormone-induced juxtaposition of regulatory elements/factors and chromatin remodeling of Crabp1 dependent on MED1/TRAP220.","date":"2005","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16137621","citation_count":58,"is_preprint":false},{"pmid":"21454576","id":"PMC_21454576","title":"Arginine and glutamate-rich 1 (ARGLU1) interacts with mediator subunit 1 (MED1) and is required for estrogen receptor-mediated gene transcription and breast cancer cell growth.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21454576","citation_count":55,"is_preprint":false},{"pmid":"22345290","id":"PMC_22345290","title":"Med1 plays a critical role in the development of tamoxifen resistance.","date":"2012","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22345290","citation_count":55,"is_preprint":false},{"pmid":"18391015","id":"PMC_18391015","title":"MED1 phosphorylation promotes its association with mediator: implications for nuclear receptor signaling.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18391015","citation_count":54,"is_preprint":false},{"pmid":"16885370","id":"PMC_16885370","title":"The DNA N-glycosylase MED1 exhibits preference for halogenated pyrimidines and is involved in the cytotoxicity of 5-iododeoxyuridine.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16885370","citation_count":53,"is_preprint":false},{"pmid":"14500757","id":"PMC_14500757","title":"The thyroid hormone receptor-associated protein TRAP220 is required at distinct embryonic stages in placental, cardiac, and hepatic development.","date":"2003","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/14500757","citation_count":52,"is_preprint":false},{"pmid":"21480322","id":"PMC_21480322","title":"Transcription coactivator mediator subunit MED1 is required for the development of fatty liver in the mouse.","date":"2011","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/21480322","citation_count":52,"is_preprint":false},{"pmid":"16314496","id":"PMC_16314496","title":"Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16314496","citation_count":51,"is_preprint":false},{"pmid":"19782026","id":"PMC_19782026","title":"Dynamic interactions and cooperative functions of PGC-1alpha and MED1 in TRalpha-mediated activation of the brown-fat-specific UCP-1 gene.","date":"2009","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/19782026","citation_count":51,"is_preprint":false},{"pmid":"8138177","id":"PMC_8138177","title":"The yeast med1 mutant undergoes both meiotic homolog nondisjunction and precocious separation of sister chromatids.","date":"1994","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8138177","citation_count":51,"is_preprint":false},{"pmid":"12556447","id":"PMC_12556447","title":"An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12556447","citation_count":49,"is_preprint":false},{"pmid":"9444950","id":"PMC_9444950","title":"Identification of RB18A, a 205 kDa new p53 regulatory protein which shares antigenic and functional properties with p53.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9444950","citation_count":48,"is_preprint":false},{"pmid":"16979152","id":"PMC_16979152","title":"Maternal deployment of the embryonic SKN-1-->MED-1,2 cell specification pathway in C. elegans.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16979152","citation_count":48,"is_preprint":false},{"pmid":"15737937","id":"PMC_15737937","title":"The noncanonical binding site of the MED-1 GATA factor defines differentially regulated target genes in the C. elegans mesendoderm.","date":"2005","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/15737937","citation_count":47,"is_preprint":false},{"pmid":"19630272","id":"PMC_19630272","title":"Conditional ablation of mediator subunit MED1 (MED1/PPARBP) gene in mouse liver attenuates glucocorticoid receptor agonist dexamethasone-induced hepatic steatosis.","date":"2009","source":"Gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/19630272","citation_count":46,"is_preprint":false},{"pmid":"34995755","id":"PMC_34995755","title":"MED1/BDNF/TrkB pathway is involved in thalamic hemorrhage-induced pain and depression by regulating microglia.","date":"2022","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/34995755","citation_count":45,"is_preprint":false},{"pmid":"15956351","id":"PMC_15956351","title":"TRAP220 is modulated by the antineoplastic agent 6-Mercaptopurine, and mediates the activation of the NR4A subgroup of nuclear receptors.","date":"2005","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15956351","citation_count":45,"is_preprint":false},{"pmid":"17827210","id":"PMC_17827210","title":"The Mediator subunit MED1/TRAP220 is required for optimal glucocorticoid receptor-mediated transcription activation.","date":"2007","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17827210","citation_count":44,"is_preprint":false},{"pmid":"17438330","id":"PMC_17438330","title":"Critical role for transcription coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein/TRAP220 in liver regeneration and PPARalpha ligand-induced liver tumor development.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17438330","citation_count":44,"is_preprint":false},{"pmid":"31894315","id":"PMC_31894315","title":"miR‑146a improves hepatic lipid and glucose metabolism by targeting MED1.","date":"2019","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31894315","citation_count":42,"is_preprint":false},{"pmid":"9892641","id":"PMC_9892641","title":"The Med1 subunit of the yeast mediator complex is involved in both transcriptional activation and repression.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9892641","citation_count":42,"is_preprint":false},{"pmid":"12430186","id":"PMC_12430186","title":"Frameshift mutations in the MBD4/MED1 gene in primary gastric cancer with high-frequency microsatellite instability.","date":"2002","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/12430186","citation_count":40,"is_preprint":false},{"pmid":"36252121","id":"PMC_36252121","title":"MED1 Regulates BMP/TGF-β in Endothelium: Implication for Pulmonary Hypertension.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36252121","citation_count":38,"is_preprint":false},{"pmid":"22331469","id":"PMC_22331469","title":"Mediator subunits MED1 and MED24 cooperatively contribute to pubertal mammary gland development and growth of breast carcinoma cells.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22331469","citation_count":38,"is_preprint":false},{"pmid":"24801167","id":"PMC_24801167","title":"Med1 subunit of the mediator complex in nuclear receptor-regulated energy metabolism, liver regeneration, and hepatocarcinogenesis.","date":"2014","source":"Gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/24801167","citation_count":36,"is_preprint":false},{"pmid":"22342682","id":"PMC_22342682","title":"Loss of Med1/TRAP220 promotes the invasion and metastasis of human non-small-cell lung cancer cells by modulating the expression of metastasis-related genes.","date":"2012","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/22342682","citation_count":36,"is_preprint":false},{"pmid":"19127118","id":"PMC_19127118","title":"Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer.","date":"2009","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19127118","citation_count":36,"is_preprint":false},{"pmid":"22189783","id":"PMC_22189783","title":"Coactivator MED1 ablation in keratinocytes results in hair-cycling defects and epidermal alterations.","date":"2011","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22189783","citation_count":36,"is_preprint":false},{"pmid":"23538858","id":"PMC_23538858","title":"ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.","date":"2013","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/23538858","citation_count":36,"is_preprint":false},{"pmid":"21098667","id":"PMC_21098667","title":"Specific erythroid-lineage defect in mice conditionally deficient for Mediator subunit Med1.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21098667","citation_count":36,"is_preprint":false},{"pmid":"18339625","id":"PMC_18339625","title":"The Med1 subunit of transcriptional mediator plays a central role in regulating CCAAT/enhancer-binding protein-beta-driven transcription in response to interferon-gamma.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18339625","citation_count":36,"is_preprint":false},{"pmid":"26849466","id":"PMC_26849466","title":"Roles of Estrogen Receptor-α and the Coactivator MED1 During Human Endometrial Decidualization.","date":"2016","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26849466","citation_count":35,"is_preprint":false},{"pmid":"33734012","id":"PMC_33734012","title":"MED1 mediator subunit is a key regulator of hepatic autophagy and lipid metabolism.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/33734012","citation_count":35,"is_preprint":false},{"pmid":"10918491","id":"PMC_10918491","title":"Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter.","date":"2000","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/10918491","citation_count":33,"is_preprint":false},{"pmid":"27548259","id":"PMC_27548259","title":"Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal Dilated Cardiomyopathy in Mice.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27548259","citation_count":32,"is_preprint":false},{"pmid":"31676563","id":"PMC_31676563","title":"Androgen Receptor Interaction with Mediator Complex Is Enhanced in Castration-Resistant Prostate Cancer by CDK7 Phosphorylation of MED1.","date":"2019","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/31676563","citation_count":32,"is_preprint":false},{"pmid":"22102282","id":"PMC_22102282","title":"Regulation of androgen receptor-dependent transcription by coactivator MED1 is mediated through a newly discovered noncanonical binding motif.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22102282","citation_count":32,"is_preprint":false},{"pmid":"21949387","id":"PMC_21949387","title":"Essential role of Mediator subunit Med1 in invariant natural killer T-cell development.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21949387","citation_count":31,"is_preprint":false},{"pmid":"24949995","id":"PMC_24949995","title":"Ablation of coactivator Med1 switches the cell fate of dental epithelia to that generating hair.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24949995","citation_count":31,"is_preprint":false},{"pmid":"15208681","id":"PMC_15208681","title":"BRCA1 function mediates a TRAP/DRIP complex through direct interaction with TRAP220.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15208681","citation_count":30,"is_preprint":false},{"pmid":"24458359","id":"PMC_24458359","title":"Cdc2-like kinase 2 suppresses hepatic fatty acid oxidation and ketogenesis through disruption of the PGC-1α and MED1 complex.","date":"2014","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/24458359","citation_count":30,"is_preprint":false},{"pmid":"19521987","id":"PMC_19521987","title":"Down-regulation of the transcriptional mediator subunit Med1 contributes to the loss of expression of metastasis-associated dapk1 in human cancers and cancer cells.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19521987","citation_count":30,"is_preprint":false},{"pmid":"11118038","id":"PMC_11118038","title":"RB18A, whose gene is localized on chromosome 17q12-q21.1, regulates in vivo p53 transactivating activity.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11118038","citation_count":28,"is_preprint":false},{"pmid":"29187405","id":"PMC_29187405","title":"HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29187405","citation_count":28,"is_preprint":false},{"pmid":"34031372","id":"PMC_34031372","title":"The KDM4B-CCAR1-MED1 axis is a critical regulator of osteoclast differentiation and bone homeostasis.","date":"2021","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/34031372","citation_count":28,"is_preprint":false},{"pmid":"32990725","id":"PMC_32990725","title":"Molecular determinants of MED1 interaction with the DNA bound VDR-RXR heterodimer.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/32990725","citation_count":27,"is_preprint":false},{"pmid":"28159809","id":"PMC_28159809","title":"Cardiac Med1 deletion promotes early lethality, cardiac remodeling, and transcriptional reprogramming.","date":"2017","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28159809","citation_count":27,"is_preprint":false},{"pmid":"15998721","id":"PMC_15998721","title":"Reevaluation of the role of the med-1 and med-2 genes in specifying the Caenorhabditis elegans endoderm.","date":"2005","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15998721","citation_count":26,"is_preprint":false},{"pmid":"33542097","id":"PMC_33542097","title":"Mediator subunit MED1 is required for E2A-PBX1-mediated oncogenic transcription and leukemic cell growth.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33542097","citation_count":25,"is_preprint":false},{"pmid":"31090264","id":"PMC_31090264","title":"Estrogen receptor coactivator Mediator Subunit 1 (MED1) as a tissue-specific therapeutic target in breast cancer.","date":"2019","source":"Journal of Zhejiang University. Science. B","url":"https://pubmed.ncbi.nlm.nih.gov/31090264","citation_count":24,"is_preprint":false},{"pmid":"20007298","id":"PMC_20007298","title":"Transcription coactivator PBP/MED1-deficient hepatocytes are not susceptible to diethylnitrosamine-induced hepatocarcinogenesis in the mouse.","date":"2009","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20007298","citation_count":24,"is_preprint":false},{"pmid":"19243021","id":"PMC_19243021","title":"Down-regulation of the expression of RB18A/MED1, a cofactor of transcription, triggers strong tumorigenic phenotype of human melanoma cells.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19243021","citation_count":23,"is_preprint":false},{"pmid":"32069354","id":"PMC_32069354","title":"USP22 controls iNKT immunity through MED1 suppression of histone H2A monoubiquitination.","date":"2020","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32069354","citation_count":23,"is_preprint":false},{"pmid":"23943624","id":"PMC_23943624","title":"The Med1 subunit of the mediator complex induces liver cell proliferation and is phosphorylated by AMP kinase.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23943624","citation_count":23,"is_preprint":false},{"pmid":"20713445","id":"PMC_20713445","title":"The transcriptional mediator subunit MED1/TRAP220 in stromal cells is involved in hematopoietic stem/progenitor cell support through osteopontin expression.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20713445","citation_count":22,"is_preprint":false},{"pmid":"31798643","id":"PMC_31798643","title":"MicroRNA-146a protects against myocardial ischaemia reperfusion injury by targeting Med1.","date":"2019","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31798643","citation_count":22,"is_preprint":false},{"pmid":"14664715","id":"PMC_14664715","title":"The different effects of endocrine-disrupting chemicals on estrogen receptor-mediated transcription through interaction with coactivator TRAP220 in uterine tissue.","date":"2003","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/14664715","citation_count":22,"is_preprint":false},{"pmid":"16324150","id":"PMC_16324150","title":"The role of transcriptional coactivator TRAP220 in myelomonocytic differentiation.","date":"2005","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/16324150","citation_count":21,"is_preprint":false},{"pmid":"16723356","id":"PMC_16723356","title":"Distinct roles of the steroid receptor coactivator 1 and of MED1 in retinoid-induced transcription and cellular differentiation.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16723356","citation_count":21,"is_preprint":false},{"pmid":"34117711","id":"PMC_34117711","title":"HOXA5 induces M2 macrophage polarization to attenuate carotid atherosclerosis by activating MED1.","date":"2021","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/34117711","citation_count":19,"is_preprint":false},{"pmid":"33888555","id":"PMC_33888555","title":"MED1 is a lipogenesis coactivator required for postnatal adipose expansion.","date":"2021","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/33888555","citation_count":18,"is_preprint":false},{"pmid":"34853629","id":"PMC_34853629","title":"MED1 Deficiency in Macrophages Accelerates Intimal Hyperplasia via ROS Generation and Inflammation.","date":"2021","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/34853629","citation_count":18,"is_preprint":false},{"pmid":"34389732","id":"PMC_34389732","title":"Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB.","date":"2021","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34389732","citation_count":18,"is_preprint":false},{"pmid":"19095651","id":"PMC_19095651","title":"Structural analysis of MED-1 reveals unexpected diversity in the mechanism of DNA recognition by GATA-type zinc finger domains.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19095651","citation_count":18,"is_preprint":false},{"pmid":"11840331","id":"PMC_11840331","title":"RB18A regulates p53-dependent apoptosis.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11840331","citation_count":17,"is_preprint":false},{"pmid":"23936234","id":"PMC_23936234","title":"Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23936234","citation_count":17,"is_preprint":false},{"pmid":"24969180","id":"PMC_24969180","title":"MicroRNA-1 functions as a potential tumor suppressor in osteosarcoma by targeting Med1 and Med31.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24969180","citation_count":17,"is_preprint":false},{"pmid":"35131256","id":"PMC_35131256","title":"MED1 Downregulation Contributes to TGFβ-Induced Metastasis by Inhibiting SMAD2 Ubiquitination Degradation in Cutaneous Melanoma.","date":"2022","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/35131256","citation_count":16,"is_preprint":false},{"pmid":"12270043","id":"PMC_12270043","title":"Comparative distribution of the mammalian mediator subunit thyroid hormone receptor-associated protein (TRAP220) mRNA in developing and adult rodent brain.","date":"2002","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12270043","citation_count":16,"is_preprint":false},{"pmid":"30087366","id":"PMC_30087366","title":"Essential role of MED1 in the transcriptional regulation of ER-dependent oncogenic miRNAs in breast cancer.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30087366","citation_count":16,"is_preprint":false},{"pmid":"22570438","id":"PMC_22570438","title":"Transcriptional analysis of brown adipose tissue in leptin-deficient mice lacking inducible nitric oxide synthase: evidence of the role of Med1 in energy balance.","date":"2012","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/22570438","citation_count":16,"is_preprint":false},{"pmid":"12485913","id":"PMC_12485913","title":"Transcriptional regulation of the human MDR1 gene at the level of the inverted MED-1 promoter region.","date":"2002","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12485913","citation_count":16,"is_preprint":false},{"pmid":"33733611","id":"PMC_33733611","title":"Med1 controls CD8 T cell maintenance through IL-7R-mediated cell survival signalling.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33733611","citation_count":15,"is_preprint":false},{"pmid":"35394046","id":"PMC_35394046","title":"Phosphorylated MED1 links transcription recycling and cancer growth.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/35394046","citation_count":15,"is_preprint":false},{"pmid":"30461303","id":"PMC_30461303","title":"Disruption of cardiac Med1 inhibits RNA polymerase II promoter occupancy and promotes chromatin remodeling.","date":"2018","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30461303","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49389,"output_tokens":10703,"usd":0.154356,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21655,"output_tokens":7924,"usd":0.153188,"stage2_stop_reason":"end_turn"},"total_usd":0.307544,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"TRAP220 (MED1) directly interacts with thyroid hormone receptor alpha (TRα) in a ligand-dependent manner, mediated through the C terminus of TRα and the LXXLL domains of TRAP220; it also shows ligand-dependent interactions with VDR, RARα, RXRα, PPARα, PPARγ, and ER. A fragment containing the LXXLL motifs acts as a dominant negative inhibitor of nuclear receptor-mediated transcription both in transfected cells and cell-free transcription systems.\",\n      \"method\": \"GST pulldown, co-immunoprecipitation, cell-free transcription assay, transfection/dominant-negative analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal in vitro and in vivo methods, replicated across many subsequent studies\",\n      \"pmids\": [\"9653119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Each of the two LXXLL-containing receptor binding domains (RBD-1 and RBD-2) of TRAP220 is differentially preferred by specific nuclear receptors: RXR prefers RBD-1, while TR, VDR, and PPARs strongly prefer RBD-2 in an AF2-dependent manner. Preference for RBD-2 is determined by basic-polar residues N-terminal to the LXXLL core. Both RBD-1 and RBD-2 are required for optimal association of TRAP220 with RXR-TR or RXR-VDR heterodimers on DNA.\",\n      \"method\": \"Site-directed mutagenesis, GST pulldown with recombinant proteins, in vitro transcription assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis, multiple receptors tested, consistent with structural data\",\n      \"pmids\": [\"10891484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TRAP220 (MED1) is an essential component required for mouse development; Trap220-null mice die during early gestation with heart failure and impaired neuronal development. Primary embryonic fibroblasts from null mutants show impaired cell cycle regulation and a prominent decrease of thyroid hormone receptor function that is restored by ectopic TRAP220, but no defect in activation by Gal4-RARα/RXRα, p53, or VP16, indicating activator-selective function.\",\n      \"method\": \"Gene knockout (null mice), primary embryonic fibroblast rescue experiments, cell-free transcription assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic knockout with defined phenotype, rescue experiment, replicated by multiple labs\",\n      \"pmids\": [\"10882104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TRAP220 (MED1) is required for PPARγ2-stimulated adipogenesis but not MyoD-stimulated myogenesis. Trap220−/− fibroblasts fail to express adipogenesis markers or PPARγ2 target genes; this is restored by exogenous TRAP220. The TRAP/Mediator complex functions directly as a transcriptional coactivator for PPARγ2 in a purified in vitro system and interacts with PPARγ2 in a ligand- and TRAP220-dependent manner.\",\n      \"method\": \"Knockout fibroblast differentiation assay, rescue by ectopic expression, purified in vitro transcription system, co-immunoprecipitation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro reconstitution plus genetic rescue, published in high-impact journal, widely replicated\",\n      \"pmids\": [\"12037571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The TRAP/Mediator complex interacts with ERα and ERβ through TRAP220 in a ligand (17β-estradiol)-dependent manner; this interaction requires TRAP220 as shown using TRAP220−/− fibroblast extracts. An ERα–TRAP/Mediator complex was isolated from cultured cells expressing epitope-tagged ERα. The complete TRAP/Mediator complex directly enhances ER function in a highly purified cell-free transcription system.\",\n      \"method\": \"Affinity pulldown from nuclear extracts, co-immunoprecipitation from cells, TRAP220−/− fibroblast extracts, purified in vitro transcription system\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods including in vitro reconstitution and genetic null validation\",\n      \"pmids\": [\"11867769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TRAP220 displays ERβ preference over ERα for recruitment, attributable to the binding specificity of the TRAP220 LXXLL motifs; the ER subtype-specific F-domain influences TRAP220 interaction.\",\n      \"method\": \"GST pulldown interaction assays, mutational analysis of LXXLL motifs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding assays with mutants, single lab, consistent with broader LXXLL mechanism\",\n      \"pmids\": [\"11303023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"An extended 13-amino-acid LXXLL motif sequence (not just the 5-residue core) determines the nuclear receptor binding specificity of TRAP220. Swapping extended LXM sequences between TRAP220 and SRC1 alters NR binding preferences.\",\n      \"method\": \"GST pulldown interaction assays, mutagenesis of LXXLL flanking regions\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis with functional readout, single lab\",\n      \"pmids\": [\"12556447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The N terminus of TRAP220 (MED1) is necessary and sufficient for stable association with the TRAP/Mediator complex, while both LXXLL (NR box) motifs are required for nuclear receptor (TR)-dependent transcription. Trap220−/− cells possess a relatively intact TRAP/Mediator complex that is specifically compromised in TR-dependent but not VP16-dependent transcription in vitro.\",\n      \"method\": \"Biochemical fractionation, transfection of TRAP220 deletion/point mutants in null cells, in vitro transcription assay with reconstituted complexes\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (biochemical + genetic + in vitro reconstitution) in a single rigorous study\",\n      \"pmids\": [\"15340084\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MED1/TRAP220 exists predominantly (>80% of total) in a TRAP/Mediator subpopulation that is enriched in specific subunits and tightly associated with near-stoichiometric RNA polymerase II. This MED1-containing holoenzyme supports basal- and activator-dependent transcription in vitro. MED1/TRAP220-containing versus MED1/TRAP220-deficient complexes are selectively recruited to ER versus p53 target genes. RNAi knockdown of MED1 is required for ER-mediated transcription and estrogen-dependent breast cancer cell growth.\",\n      \"method\": \"Biochemical fractionation/mass spectrometry, in vitro transcription, chromatin immunoprecipitation, RNAi knockdown\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal approaches (biochemistry, ChIP, functional RNAi) in a single rigorous study\",\n      \"pmids\": [\"15989967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ERK (MAPK) phosphorylates TRAP220/MED1 in vivo at two specific sites: threonine 1032 and threonine 1457. ERK phosphorylation increases the stability and half-life of TRAP220/MED1, correlates with increased thyroid hormone receptor-dependent transcription, occurs in a cell cycle-dependent manner (peak at G2/M), and triggers shuttling into the nucleolus.\",\n      \"method\": \"In vivo phosphorylation mapping, cell cycle synchronization, in vitro kinase assay, transcription reporter assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — site-specific phosphorylation mapped in vitro and in vivo, functional consequences characterized, replicated in follow-up studies\",\n      \"pmids\": [\"16314496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In Med1/Trap220-null cells, thyroid hormone (T3)-induced chromatin remodeling events at the Crabp1 locus — including juxtaposition of the TRE and GC box regions, nucleosome sliding, replacement of BRM by BRG1, and histone hyperacetylation — are all abolished, indicating a key role for TRAP/Mediator in these processes. A MED1/TRAP220-containing Mediator complex constitutively occupies the GC box region, serving as a nexus for distal and proximal factors.\",\n      \"method\": \"Chromatin immunoprecipitation, null cell genetics, chromatin remodeling assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — null cell genetics plus ChIP, multiple chromatin endpoints, consistent with broader Mediator mechanism\",\n      \"pmids\": [\"16137621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MED1 (MED14 and MED1) are used by glucocorticoid receptor (GR) in a gene-specific manner: ladinin 1 and IRF8 induction requires both MED1 and MED14, IGFBP1 induction requires MED14 but not MED1, and GILZ induction is largely independent of both.\",\n      \"method\": \"siRNA knockdown in U2OS-hGR cells, RT-PCR of endogenous GR target genes, ChIP\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi with endogenous gene readouts and ChIP, single lab\",\n      \"pmids\": [\"16239257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Mediator subunit Med1/TRAP220 physically interacts with the erythroid master regulator GATA-1 and is required for GATA-1-mediated transactivation. Med1-deficient embryos are anemic with defects in erythroid burst-forming units and colony-forming units but not in myeloid colonies. Mediator components occupy GATA-1-occupied enhancer sites by ChIP.\",\n      \"method\": \"Co-immunoprecipitation, transactivation assay in Med1-null cells, colony formation assay from Med1-null embryos, chromatin immunoprecipitation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic null model with specific hematopoietic phenotype, physical interaction, and ChIP, replicated in conditional knockout\",\n      \"pmids\": [\"17132730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ERK phosphorylation of MED1 promotes its association with the Mediator complex via direct binding to the MED7 subunit; ERK phosphorylation enhances the MED1–MED7 interaction. Both thyroid and steroid hormones stimulate MED1 phosphorylation in vivo, and MED1 phosphorylation is required for its nuclear hormone receptor coactivator activity. ERK phosphorylation of MED1 enhances TR-dependent transcription in vitro.\",\n      \"method\": \"Co-immunoprecipitation of MED1 with MED7, in vivo phosphorylation by hormone treatment, in vitro transcription assay, phosphorylation-deficient mutants\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct binding partner (MED7) identified, in vitro and in vivo phosphorylation, functional consequence in transcription\",\n      \"pmids\": [\"18391015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Med1 subunit of the Mediator complex is required for IFN-γ-induced C/EBPβ-driven transcription. Med1 associates with C/EBPβ through a domain located between amino acids 125 and 155 of its N-terminus; ERK1/2-mediated phosphorylation of C/EBPβ at Thr189 is essential for its binding to Med1, and an ERK-regulated site in Med1 is required for IFN-induced transcription.\",\n      \"method\": \"Co-immunoprecipitation, Med1 knockout cells, RNAi, mutagenesis of binding and phosphorylation sites\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (KO cells, RNAi, mutagenesis, Co-IP), single lab\",\n      \"pmids\": [\"18339625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PGC-1α is recruited to the TRα–RXRα–UCP-1 enhancer complex through interaction of an N-terminal LXXLL domain with TRα. MED1/Mediator then displaces PGC-1α from TRα through LXXLL domain competition; upon displacement, PGC-1α remains associated with the enhancer through an interaction between PGC-1α and MED1 C-terminal domains. Med1 is required for UCP-1 induction in brown adipocytes.\",\n      \"method\": \"Biochemical competition assays, co-immunoprecipitation, chromatin immunoprecipitation, Med1 RNAi in primary brown adipocytes\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — biochemical reconstitution of competition mechanism, ChIP, and genetic knockdown in a single rigorous study\",\n      \"pmids\": [\"19782026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MED1 LxxLL motif knockin mice exhibit severe defects in pubertal mammary gland development with loss of ERα-Mediator interaction, down-regulation of ERα-regulated genes, and impaired mammary luminal epithelial cell differentiation. MED1 is differentially expressed in different types of mammary epithelial cells.\",\n      \"method\": \"Knockin mouse model (LxxLL motif mutations), mammary gland histology, gene expression analysis, ChIP\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockin genetics with specific mammary phenotype and molecular readouts\",\n      \"pmids\": [\"20351249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Skeletal muscle-specific Med1 knockout mice show enhanced insulin sensitivity, improved glucose tolerance, resistance to high-fat diet-induced obesity, increased mitochondrial density, and a fast-to-slow fiber switch with increased expression of UCP-1 and Cidea genes, implicating MED1 as a suppressor of energy expenditure genetic programs in skeletal muscle.\",\n      \"method\": \"Tissue-specific conditional knockout, metabolic phenotyping, gene expression profiling\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean tissue-specific KO with defined metabolic phenotype, single lab\",\n      \"pmids\": [\"20479251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CRPC-specific enhancers drive UBE2C overexpression through MED1 recruitment. PI3K/AKT-phosphorylated MED1 mediates recruitment of FoxA1, RNA polymerase II, and TATA-binding protein to the UBE2C locus, driving long-range enhancer/promoter looping and UBE2C gene expression and cell growth.\",\n      \"method\": \"ChIP, chromosome conformation capture (3C), RNAi knockdown, phospho-mutant constructs, cell growth assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — 3C looping assay, ChIP, phospho-mutant functional rescue, multiple orthogonal methods\",\n      \"pmids\": [\"21556051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MED1 directly interacts with the E2A activation domain and is specifically required for E2A-PBX1-dependent gene activation and leukemic cell growth. RUNX1 recruits E2A-PBX1 to chromatin and this interaction can be stabilized by EBF1.\",\n      \"method\": \"Co-immunoprecipitation, CRISPR/Cas9 MED1 depletion, transcriptome and cistrome analysis, in vitro binding assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct interaction mapped, CRISPR KO with transcriptomic readout, single lab\",\n      \"pmids\": [\"33542097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ARGLU1 directly interacts with a far C-terminal region of MED1, co-localizes with MED1 in the nucleus, cooperates with MED1 to regulate ER-mediated gene transcription, and is recruited in a ligand-dependent manner to endogenous ER target gene promoters; co-occupancy of ARGLU1 and MED1 on the same ER target gene promoter was confirmed by ChIP-reChIP.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, ChIP and ChIP-reChIP, reporter assay, RNAi\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct interaction with domain mapping, ChIP-reChIP co-occupancy, functional RNAi, single lab\",\n      \"pmids\": [\"21454576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MED1 is a novel cross-talk point for HER2 and ERα pathways. MED1 is phosphorylated by HER2 signaling at a site critical for its activation. Phosphorylated MED1 is recruited to ERα target gene promoters by tamoxifen in HER2-overexpressing cells; RNAi attenuation of MED1 or mutation of its phosphorylation sites restores recruitment of corepressors N-CoR and SMRT. MED1 is also required for HER2 gene expression itself.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, RNAi knockdown, phospho-mutant constructs, tissue microarray\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with phospho-mutants and RNAi, consistent mechanism, single lab\",\n      \"pmids\": [\"22964581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"T cell-specific Med1 deficiency causes a specific block in iNKT cell development but conventional αβ T cell development remains largely normal. The defect is cell-intrinsic and is rescued by ectopic Vα14-Jα18 TCR transgene expression. Thymic iNKT cells in Med1-null animals display reduced IL-2Rβ and T-bet expression.\",\n      \"method\": \"T cell-specific conditional knockout, flow cytometry, TCR transgene rescue experiment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean conditional KO with cell-intrinsic rescue, single lab\",\n      \"pmids\": [\"21949387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Med1-specific conditional knockout in erythroid lineage causes a complete block in erythroid development (absence of β-globin gene expression) but not in myeloid or lymphoid development. Dynamic recruitment of GATA-1, TFIIB, Mediator, and RNA polymerase II to the β-globin locus was demonstrated in induced erythroid cells.\",\n      \"method\": \"Med1 conditional knockout mice, ChIP time-course in induced erythroid cells, gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with lineage-specific phenotype plus dynamic ChIP of Mediator at the β-globin locus\",\n      \"pmids\": [\"21098667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MED1 is required for androgen receptor (AR)-mediated transcription through a non-canonical interaction: MED1 binds to the AR N-terminal transactivation unit-1 (Tau-1) via two newly discovered non-canonical α-helical motifs between MED1 residues 505–537, not through its two LXXLL motifs. Loss of the AR N/C intramolecular interaction decreases MED1 binding. MAPK phosphorylation of MED1 enhances the AR–MED1 interaction in prostate cancer cells.\",\n      \"method\": \"Co-immunoprecipitation with deletion/point mutants, in vitro binding assay, reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — domain mapping by mutagenesis and co-IP, single lab\",\n      \"pmids\": [\"22102282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MED1 and MED24 cooperatively contribute to pubertal mammary gland development; MED1/MED24 double heterozygous knockout mice show profound ductal branching retardation during puberty while single haploinsufficient glands develop normally. The cooperation is mediated through ER-dependent regulation of E2F1 and cyclin D1 expression.\",\n      \"method\": \"Double heterozygous knockout mouse model, mammary gland histology, gene expression analysis, reporter assay in double-mutant MEFs\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — compound genetic mouse model with defined mammary phenotype, single lab\",\n      \"pmids\": [\"22331469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"AMP-activated protein kinase (AMPK) directly interacts with Med1 and phosphorylates Med1 in vitro at serine 656, serine 756, and serine 796. AMPK also phosphorylates Med1 in vivo in mouse liver and cultured cells. AMPK inhibition decreases Med1-induced hepatocyte proliferation and PPARα activator-inducible fatty acid β-oxidation in liver.\",\n      \"method\": \"In vitro kinase assay with recombinant proteins, in vivo phosphorylation by adenoviral overexpression, AMPK inhibitor compound C, liver-specific overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct in vitro kinase assay with site mapping, in vivo phosphorylation confirmed, functional consequence shown, single lab\",\n      \"pmids\": [\"23943624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Clk2 (Cdc2-like kinase 2) phosphorylates PGC-1α, which disrupts the interaction between PGC-1α and Mediator subunit MED1, suppressing PGC-1α activation of PPARα target genes in fatty acid oxidation and ketogenesis.\",\n      \"method\": \"Co-immunoprecipitation of PGC-1α–MED1 complex, in vitro kinase assay, liver-specific Clk2 knockout, primary hepatocyte manipulation\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro kinase assay, Co-IP disruption, conditional KO metabolic phenotype, single lab\",\n      \"pmids\": [\"24458359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PRDM16 directly interacts with MED1 through its zinc finger domains, is recruited to the Ucp1 enhancer through this interaction, and enhances TR-driven transcription in a biochemically defined system in a Mediator-dependent manner. Cell-based studies confirmed MED1 and TR dependency for PRDM16-induced Ucp1 expression.\",\n      \"method\": \"GST pulldown, co-immunoprecipitation, in vitro transcription with purified components, ChIP, RNAi knockdown\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro reconstitution with direct interaction mapping, ChIP, and cell-based genetic validation in a single study\",\n      \"pmids\": [\"25644605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"cAMP-dependent protein kinase A (PKA) phosphorylates MED1 during human endometrial stromal cell (HESC) decidualization. PKA-phosphorylated MED1 interacts with ESR1 (ERα), and this phosphorylation correlates with enhanced MED1 recruitment to estrogen-responsive elements in the WNT4 gene. MED1 knockdown impairs ESR1-induced WNT4 and FOXO1 expression and blocks decidualization.\",\n      \"method\": \"Immunoprecipitation, kinase assay, ChIP, RNAi knockdown in primary HESCs\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP, ChIP, and RNAi in primary cells, single lab\",\n      \"pmids\": [\"26849466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MED1 undergoes CDK7-dependent phosphorylation at T1457 and physically engages AR at superenhancer sites. CDK7 inhibition (THZ1) blocks AR/MED1 co-recruitment genome-wide, reverses the hyperphosphorylated MED1-associated enzalutamide-resistant phenotype, and induces tumor regression of AR-amplified CRPC in a xenograft model.\",\n      \"method\": \"ChIP-seq, co-immunoprecipitation, CDK7 inhibitor THZ1, xenograft tumor model, phospho-mutant analysis\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq, direct interaction, in vivo xenograft, phospho-specific functional analysis\",\n      \"pmids\": [\"31466944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Structural and biophysical analyses of MED1 interaction with the VDR–RXR heterodimer bound to DNA reveal that ligand-dependent interaction between VDR and the second coactivator motif (LXM2) of MED1 is crucial for complex formation. Additionally, RXR regions interact with the structured N-terminal domain of MED1, and VDR regions outside the classical coactivator binding cleft are affected by coactivator recruitment.\",\n      \"method\": \"Structural biology (combination of methods), biophysical binding assays (SEC, native MS), mutational analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural/biophysical characterization with mutagenesis, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"32990725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"USP22 interacts with MED1 but does not deubiquitinate MED1 directly. Instead, USP22 enhances MED1 transcriptional activation functions for IL-2Rβ and T-bet gene expression through deubiquitinating histone H2A (not H2B) monoubiquitination, establishing a USP22–histone H2A deubiquitination–MED1 axis in iNKT cell development.\",\n      \"method\": \"Co-immunoprecipitation, iNKT-specific conditional knockout, ubiquitination assay, gene expression analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct Co-IP, ubiquitination biochemistry, and KO phenotype, single lab\",\n      \"pmids\": [\"32069354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"KDM4B physically and functionally associates with CCAR1 and MED1 in a complex. Genome-wide ChIP-seq shows the KDM4B–CCAR1–MED1 complex is localized to promoters of osteoclast-related genes upon RANKL stimulation; the complex induces euchromatinization through H3K9 demethylation, enabling NF-κB p65 recruitment via direct interaction between KDM4B and p65.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, H3K9 methylation assay, conditional knockout mice, small molecule inhibitor\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP complex identification, genome-wide ChIP-seq, and KO phenotype, single lab\",\n      \"pmids\": [\"34031372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MED1 is required for postnatal adipose expansion and induction of fatty acid/triglyceride synthesis genes when pups switch from high-fat maternal milk to carbohydrate-based chow. Mechanistically, MED1 facilitates lipogenic transcription factor ChREBP- and SREBP1a-dependent recruitment of Mediator to active enhancers. MED1 is dispensable for adipose development and for PPARγ/C/EBPα induction during adipogenesis.\",\n      \"method\": \"Adipose-specific conditional knockout, ChIP for ChREBP/SREBP1a and Mediator, gene expression profiling\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with ChIP mechanistic data, single lab\",\n      \"pmids\": [\"33888555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MED1, when phosphorylated at T1032 by CDK9, dynamically moves with RNA polymerase II throughout transcribed genes to drive Pol II recycling after the initial round of transcription. MED31 mediates the recycling of phosphorylated MED1 and Pol II, enhancing mRNA output. MED1 phosphorylation increases during prostate cancer progression and CDK9 inhibition decreases MED1 phosphorylation and Pol II recycling.\",\n      \"method\": \"In vitro and in vivo transcription recycling assays, phospho-mutant analysis, CDK9 inhibitor, prostate cancer progression analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro reconstitution of transcription recycling, mechanistic phospho-mutant analysis, and in vivo validation\",\n      \"pmids\": [\"35394046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"RB18A (MED1/TRAP220) interacts in vitro with p53 through its C-terminal domain, binds DNA, self-oligomerizes, and regulates p53 specific binding to its DNA consensus site. RB18A activated the Bax promoter and inhibited p21Waf1 or IGF-BP3 promoters driven by p53 in vivo; RB18A interacts with p53 in vivo.\",\n      \"method\": \"Co-immunoprecipitation with p53, in vitro pulldown, transfection reporter assay with p53-responsive promoters\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and reporter assays, single lab, not extensively followed up for this specific function\",\n      \"pmids\": [\"9444950\", \"11118038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BRCA1's BRCT domain directly interacts with TRAP220 (MED1) in vitro and in vivo; BRCT point mutations found in patients that lack transactivation function abolish this interaction. BRCA1 transactivation function depends on TRAP220 expression levels, and antisense TRAP220 significantly reduces survival of BRCA1-expressing cells after DNA damage.\",\n      \"method\": \"GST pulldown, co-immunoprecipitation, transient expression reporter assay, BRCT point mutant analysis, cell survival assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reciprocal Co-IP and GST pulldown with functional readouts, single lab\",\n      \"pmids\": [\"15208681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MED1 in bone marrow stromal cells supports hematopoietic stem/progenitor cells through VDR- and Runx2-mediated expression of osteopontin (OPN). Med1-null MEFs show attenuated OPN expression and Mediator recruitment to the Opn promoter; addition of OPN to Med1-null MEF co-cultures restores hematopoietic progenitor growth.\",\n      \"method\": \"Med1 knockout MEF co-culture with bone marrow cells, ChIP, gene expression analysis, OPN rescue experiment\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null cells with ChIP and rescue experiment, single lab\",\n      \"pmids\": [\"20713445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cardiac-specific Med1 deletion reduces RNA polymerase II occupancy at the majority of transcriptional start sites (increased pausing index) without a corresponding increase in elongating species. Med1-dependent gene expression strongly correlates with H3K27 acetylation at TSS; H3K27me3 levels are broadly increased upon Med1 deletion. Med1 determines chromatin accessibility within genes and at enhancer regions.\",\n      \"method\": \"ChIP-seq for Pol II, H3K27ac, H3K27me3 in cardiac Med1 knockout versus floxed control mice\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-seq in conditional KO, single lab\",\n      \"pmids\": [\"30461303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Med1 controls CD8+ T cell peripheral maintenance through IL-7Rα/STAT5 pathway-mediated cell survival. T cell-specific Med1 deletion reduces CD8+ T cell proportion in spleen in a cell-intrinsic manner (competitive transfer confirmed), with increased cell death, decreased IL-7Rα expression, reduced pSTAT5, and elevated Bim.\",\n      \"method\": \"T cell-specific conditional knockout, competitive bone marrow transfer, flow cytometry, gene expression analysis\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with cell-intrinsic competitive transfer, signaling pathway readouts, single lab\",\n      \"pmids\": [\"33733611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MED1 acts synergistically with KLF4 to transactivate BMPR2, ERG, and TGFBR2 in pulmonary endothelial cells via chromatin remodeling and enhancer-promoter interactions. EC-specific MED1 knockout mice show pulmonary hypertension susceptibility; MED1 overexpression mitigates PH phenotype in rodents. MED1 levels are decreased in lung tissue from idiopathic PAH patients.\",\n      \"method\": \"RNA-seq, MED1 ChIP-seq, H3K27ac ChIP-seq, ATAC-seq, Hi-C, endothelial-specific MED1 knockout mice, adenoviral MED1 overexpression\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multi-omic approach (ChIP-seq, ATAC-seq, Hi-C), conditional KO, and overexpression in vivo model\",\n      \"pmids\": [\"36252121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MED1 interacts with SMAD2 and MED1 downregulation protects SMAD2 from ubiquitination-dependent degradation, thereby enhancing TGFβ/SMAD2 signaling, epithelial-to-mesenchymal transition, and metastasis in cutaneous melanoma.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, RNAi knockdown, in vivo xenograft metastasis model\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP, ubiquitination biochemistry, in vivo metastasis model, single lab\",\n      \"pmids\": [\"35131256\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MED1 (TRAP220) is a pivotal subunit of the Mediator coactivator complex that anchors the complex to diverse nuclear receptors (TR, VDR, PPARγ, ER, GR, AR, and others) through ligand-dependent interactions mediated by two LXXLL motifs (and, for AR, via a distinct non-canonical motif), recruits RNA polymerase II to target gene promoters, undergoes regulatory phosphorylation by ERK, CDK7, CDK9, AMPK, and PKA at specific residues to modulate its stability, complex association, and transcriptional activity, and is required for transcription of diverse gene programs controlling adipogenesis, erythropoiesis, cardiac function, mammary gland development, energy metabolism, and immune cell development—with CDK9-phosphorylated MED1 additionally traveling with Pol II to drive transcription recycling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MED1 (TRAP220) is the Mediator-complex subunit that couples ligand-activated nuclear receptors and other DNA-bound activators to the RNA polymerase II transcription machinery, and it is required for diverse developmental and metabolic gene programs [#0, #2, #8]. It binds thyroid hormone receptor, VDR, RAR/RXR, PPARs, and ER in a ligand-dependent manner through two LXXLL (NR-box) motifs, with individual receptors preferring RBD-1 versus RBD-2 according to residues flanking the LXXLL core, while a non-canonical α-helical motif (residues 505–537) mediates a distinct interaction with the androgen receptor N-terminal transactivation domain [#0, #1, #6, #24]. The N terminus anchors MED1 stably within the Mediator/Pol II holoenzyme, whereas the LXXLL motifs are dispensable for complex integrity but required for receptor-dependent transcription, defining MED1 as an activator-selective adaptor: Med1-null cells assemble a largely intact Mediator yet are specifically defective in TR-, ER-, PPARγ-, and GATA-1-dependent transcription while remaining competent for VP16- and p53-driven activation [#2, #7, #8, #3, #12]. Mechanistically MED1-containing Mediator constitutively occupies target loci and orchestrates chromatin remodeling, nucleosome sliding, histone acetylation, enhancer–promoter looping, and recruitment of Pol II, TBP, and pioneer factors such as FoxA1 [#10, #18, #39]. MED1 activity is tuned by a phosphorylation code: ERK phosphorylation at T1032/T1457 stabilizes MED1, promotes its MED7-dependent association with Mediator, and triggers nucleolar shuttling; CDK7 phosphorylation at T1457 drives AR co-recruitment at superenhancers; CDK9 phosphorylation at T1032 enables MED1 to travel with elongating Pol II for transcription recycling via MED31; and AMPK and PKA phosphorylate MED1 to regulate hepatic and decidualization programs [#9, #13, #30, #35, #26, #29]. Through these activities MED1 is genetically required for early embryogenesis and cardiac/neuronal development, adipogenesis and lipogenesis, brown-fat thermogenic gene induction, erythropoiesis and β-globin expression, mammary ductal development, iNKT and CD8 T-cell development, and pulmonary endothelial homeostasis [#2, #3, #34, #15, #28, #12, #23, #16, #22, #40, #41]. It additionally serves as an integration node for cofactors and signaling partners including PGC-1α, PRDM16, ARGLU1, KDM4B/CCAR1, BRCA1, p53, and SMAD2 [#15, #28, #20, #33, #37, #36, #42].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Before MED1 was placed in Mediator, an early activity established it as a p53-associated factor capable of modulating p53 target-gene selectivity, framing it as a transcriptional regulator.\",\n      \"evidence\": \"Co-IP and p53-responsive promoter reporter assays (RB18A)\",\n      \"pmids\": [\"9444950\", \"11118038\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not place this p53 activity within the Mediator complex\", \"Functional significance not extensively followed up\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined MED1 as a direct ligand-dependent nuclear-receptor coactivator, answering how the receptor signal reaches the basal machinery.\",\n      \"evidence\": \"GST pulldown, Co-IP, cell-free transcription, and dominant-negative LXXLL fragment across TRα, VDR, RAR/RXR, PPARs, ER\",\n      \"pmids\": [\"9653119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which LXXLL motif serves which receptor\", \"Did not establish in vivo requirement\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Resolved the molecular basis of receptor selectivity and demonstrated organismal essentiality with activator-selective function.\",\n      \"evidence\": \"LXXLL mutagenesis defining RBD-1/RBD-2 preference, and Trap220-null mice with embryonic lethality plus rescue in null MEFs\",\n      \"pmids\": [\"10891484\", \"10882104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking MED1 loss to heart failure not defined\", \"Cell-cycle defect mechanism not explained\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Established gene-program-specific requirements, showing MED1 is required for PPARγ-driven adipogenesis and ER function but not all activators.\",\n      \"evidence\": \"Knockout fibroblast differentiation/rescue, purified in vitro transcription, and TRAP220-null extracts for ER\",\n      \"pmids\": [\"12037571\", \"11867769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address how a single subunit confers program selectivity\", \"ER subtype preference not yet resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Refined the determinant of receptor specificity to an extended 13-residue LXXLL context, explaining differential receptor recruitment.\",\n      \"evidence\": \"GST pulldown with swapped extended LXM sequences between TRAP220 and SRC1\",\n      \"pmids\": [\"12556447\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis not directly visualized\", \"Single lab\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Dissected MED1 architecture, separating complex-anchoring (N terminus) from receptor-coupling (LXXLL) functions, and clarified that null cells retain Mediator.\",\n      \"evidence\": \"Biochemical fractionation, deletion/point mutants in null cells, in vitro transcription reconstitution\",\n      \"pmids\": [\"15340084\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define how the N terminus integrates into the complex structurally\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Extended MED1 partners beyond nuclear receptors to BRCA1, linking it to DNA-damage survival.\",\n      \"evidence\": \"GST pulldown, Co-IP, BRCT point-mutant analysis, cell survival assay\",\n      \"pmids\": [\"15208681\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of MED1 in DNA-damage response not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed MED1 marks a distinct Pol II-associated Mediator subpopulation selectively recruited to specific genes, and linked it to ER-driven breast cancer growth.\",\n      \"evidence\": \"Biochemical fractionation/MS, in vitro transcription, ChIP, RNAi\",\n      \"pmids\": [\"15989967\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants partitioning MED1 into the subpopulation unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Connected MED1 to chromatin remodeling and identified ERK phosphorylation as a stability/activity switch, beginning the MED1 phospho-code.\",\n      \"evidence\": \"ChIP/chromatin remodeling at Crabp1 in null cells; in vivo phospho-mapping at T1032/T1457, cell-cycle synchronization, kinase assays\",\n      \"pmids\": [\"16137621\", \"16314496\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nucleolar shuttling functional role unresolved\", \"How remodeling enzymes are recruited not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated gene-specific Mediator subunit usage by glucocorticoid receptor, showing MED1 dependence is target-dependent.\",\n      \"evidence\": \"siRNA in U2OS-hGR, endogenous target RT-PCR, ChIP\",\n      \"pmids\": [\"16239257\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Basis of gene-specific MED1 dependence unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established MED1 as a lineage-specific coactivator for the erythroid master regulator GATA-1.\",\n      \"evidence\": \"Co-IP, transactivation in null cells, colony assays from null embryos, ChIP\",\n      \"pmids\": [\"17132730\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve developmental stage of requirement (addressed later)\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mechanistically explained ERK phosphorylation by identifying MED7 as the phospho-dependent binding partner that incorporates MED1 into Mediator.\",\n      \"evidence\": \"Co-IP of MED1 with MED7, hormone-induced phosphorylation, phospho-deficient mutants, in vitro transcription\",\n      \"pmids\": [\"18391015\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry/structural detail of MED1-MED7 contact not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Broadened MED1 coactivation to a non-receptor activator (C/EBPβ) in IFN-γ signaling, with phosphorylation gating the interaction.\",\n      \"evidence\": \"Co-IP, KO cells, RNAi, mutagenesis of binding/phospho sites\",\n      \"pmids\": [\"18339625\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genome-wide scope of C/EBPβ-MED1 program not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Revealed a hand-off mechanism in which MED1/Mediator displaces PGC-1α from TRα while retaining it on the enhancer, integrating cofactors at the Ucp1 enhancer.\",\n      \"evidence\": \"Biochemical competition, Co-IP, ChIP, RNAi in brown adipocytes\",\n      \"pmids\": [\"19782026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics of the hand-off in vivo not directly observed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established the in vivo requirement of the MED1 LXXLL motifs for ERα-driven mammary development and the role in bone-marrow-stromal support of hematopoiesis.\",\n      \"evidence\": \"LxxLL knockin mice with mammary histology and ChIP; Med1-null MEF co-culture with OPN rescue\",\n      \"pmids\": [\"20351249\", \"20713445\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"OPN axis tested in MEFs rather than primary stroma\", \"Knockin study single lab for mammary\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed MED1 acts as a suppressor of energy-expenditure programs in skeletal muscle, defining a tissue-specific repressive metabolic role.\",\n      \"evidence\": \"Muscle-specific conditional KO, metabolic phenotyping, expression profiling\",\n      \"pmids\": [\"20479251\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets in muscle not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Pinned the erythroid requirement to a specific developmental block and showed dynamic Mediator/Pol II recruitment at the β-globin locus.\",\n      \"evidence\": \"Erythroid conditional KO, ChIP time-course, expression analysis\",\n      \"pmids\": [\"21098667\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why erythroid but not myeloid/lymphoid lineages depend on MED1 not fully resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined a non-canonical, LXXLL-independent mode of MED1 binding to AR and linked AR/MED1 to enhancer looping and oncogenic UBE2C expression in castration-resistant prostate cancer.\",\n      \"evidence\": \"Co-IP domain mapping (residues 505–537); ChIP, 3C, phospho-mutants, growth assays for UBE2C\",\n      \"pmids\": [\"22102282\", \"21556051\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural detail of the non-canonical AR motif not resolved\", \"PI3K/AKT phospho-site identity for UBE2C not fully mapped\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Expanded MED1 cofactor partnerships (ARGLU1, E2A) and immune roles (iNKT development), and positioned MED1 in HER2-ER crosstalk and tamoxifen response.\",\n      \"evidence\": \"Co-IP/ChIP-reChIP (ARGLU1); CRISPR/Co-IP (E2A); conditional KO + TCR transgene rescue (iNKT); ChIP/RNAi/phospho-mutants (HER2)\",\n      \"pmids\": [\"21454576\", \"33542097\", \"21949387\", \"22964581\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Several interactions rest on single-lab Co-IP\", \"HER2-MED1 phospho-site precise identity not fully defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated cooperative Mediator subunit dosage (MED1+MED24) in ER-dependent mammary proliferation via E2F1/cyclin D1.\",\n      \"evidence\": \"Double heterozygous KO mice, histology, expression, reporter assays\",\n      \"pmids\": [\"22331469\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct cooperativity mechanism between subunits not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Added AMPK to the MED1 kinase set, mapping hepatic phosphosites controlling PPARα-dependent fatty acid oxidation.\",\n      \"evidence\": \"In vitro kinase assay with site mapping (S656/S756/S796), in vivo phosphorylation, AMPK inhibition, liver overexpression\",\n      \"pmids\": [\"23943624\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of individual AMPK sites not separated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed that kinase regulation of the PGC-1α–MED1 interface (via Clk2 phosphorylation of PGC-1α) gates hepatic fatty acid oxidation and ketogenesis.\",\n      \"evidence\": \"Co-IP disruption, in vitro kinase assay, liver-specific Clk2 KO, primary hepatocytes\",\n      \"pmids\": [\"24458359\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"MED1 residues involved in PGC-1α binding not mapped here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified PRDM16 as a zinc-finger-mediated MED1 partner that recruits Mediator to the Ucp1 enhancer to enhance TR-driven thermogenic transcription.\",\n      \"evidence\": \"GST pulldown, Co-IP, in vitro transcription with purified components, ChIP, RNAi\",\n      \"pmids\": [\"25644605\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo requirement of the PRDM16-MED1 contact not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Added PKA-dependent MED1 phosphorylation as the signal coupling ESR1 to decidualization gene expression.\",\n      \"evidence\": \"IP, kinase assay, ChIP, RNAi in primary endometrial stromal cells\",\n      \"pmids\": [\"26849466\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PKA phosphosite on MED1 not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided genome-wide evidence that MED1 controls Pol II promoter occupancy/pausing and chromatin state in cardiac tissue, linking it to H3K27ac/H3K27me3 balance.\",\n      \"evidence\": \"ChIP-seq for Pol II/H3K27ac/H3K27me3 in cardiac conditional KO\",\n      \"pmids\": [\"30461303\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal hierarchy between Pol II loss and chromatin changes not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected CDK7 phosphorylation of MED1 T1457 to AR superenhancer engagement and enzalutamide resistance, establishing a therapeutic vulnerability.\",\n      \"evidence\": \"ChIP-seq, Co-IP, CDK7 inhibitor THZ1, xenograft, phospho-mutants\",\n      \"pmids\": [\"31466944\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability beyond AR-amplified CRPC not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Provided structural/biophysical resolution of MED1 engagement with DNA-bound VDR-RXR, confirming LXM2 as the critical ligand-dependent contact plus RXR–N-terminal-domain interactions.\",\n      \"evidence\": \"Structural biology, SEC/native MS, mutational analysis\",\n      \"pmids\": [\"32990725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full Mediator-receptor architecture not resolved\", \"Single receptor pair\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined an indirect cofactor mechanism (USP22 deubiquitinates histone H2A, not MED1) enabling MED1 activation of iNKT developmental genes.\",\n      \"evidence\": \"Co-IP, iNKT conditional KO, ubiquitination assay, expression analysis\",\n      \"pmids\": [\"32069354\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct chromatin co-occupancy of USP22-MED1 not mapped genome-wide\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed MED1 in a KDM4B-CCAR1 H3K9-demethylase complex enabling NF-κB-driven osteoclast gene activation, and expanded metabolic roles to postnatal lipogenesis via ChREBP/SREBP1a and CD8 T-cell maintenance via IL-7Rα/STAT5.\",\n      \"evidence\": \"Co-IP/ChIP-seq/KO (KDM4B); adipose conditional KO + ChIP (lipogenesis); T-cell KO + competitive transfer (CD8)\",\n      \"pmids\": [\"34031372\", \"33888555\", \"33733611\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect contributions of MED1 in each complex not fully separated\", \"Single-lab studies\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established the CDK9-MED1 T1032-MED31 axis driving Pol II recycling/elongation, and added vascular (KLF4-MED1) and oncogenic (SMAD2 stabilization) functions.\",\n      \"evidence\": \"In vitro/in vivo recycling assays, phospho-mutants, CDK9 inhibition (recycling); multi-omic + EC KO (KLF4/PH); Co-IP/ubiquitination/xenograft (SMAD2)\",\n      \"pmids\": [\"35394046\", \"36252121\", \"35131256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How MED31 selects phospho-MED1/Pol II cargo not fully resolved\", \"SMAD2 mechanism single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the MED1 phosphorylation code (ERK/CDK7/CDK9/AMPK/PKA at distinct residues) is integrated to dictate which activator program, complex association, and elongation/recycling outcome predominates in a given cell type remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking individual phosphosites to specific gene programs\", \"Structural basis of activator-selective Mediator partitioning unknown\", \"Crosstalk among the five kinases not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 8, 12]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 3, 4, 15]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 7, 13, 28]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [36]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8, 20]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [8, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 7, 8, 35]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [10, 33, 39, 41]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 3, 16, 23]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 15, 17, 26, 34]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 14, 21, 42]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 22, 32, 40]}\n    ],\n    \"complexes\": [\n      \"Mediator complex (TRAP/Mediator)\",\n      \"Mediator-Pol II holoenzyme\",\n      \"KDM4B-CCAR1-MED1 complex\"\n    ],\n    \"partners\": [\n      \"MED7\",\n      \"PGC-1alpha\",\n      \"PRDM16\",\n      \"GATA1\",\n      \"ARGLU1\",\n      \"MED31\",\n      \"BRCA1\",\n      \"SMAD2\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}